Global Liquid Biopsy Products Market By Application (Circulating tumor cells (CTC) in the blood, Cell free DNA from tumor or fetus cells (in the blood), Molecular Diagnostics, Early Stage Cancer – Lung Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer, Prostate Cancer, Liver Cancer, Bladder Cancer, Ovarian Cancer, Others, Non-invasive prenatal tests (NIPT), Others); By Size (5 ml, 50 ml, 100 ml, 250 ml, Above 250 ml); By Offering (Instruments – Blood Collection Tube (BCT) for cfDNA and CTCs, Target Selector Kits, Cell Free DNA Extraction Kit, Cell Free Nucleic Acid Extraction Kit, Mutation Quantification Control Plasma, Genomic profiling diagnostic kit, Target Selector NGS Panels, PCR Purification Kit, Blood Nucleic Acid Extraction, Viral Nucleic Acid Extraction, Others, Reagents, Liquid Biopsy Assays, Tools, Services – Custom Services, Support Services, Others); By End User (Hospitals/ Clinics, Pathology Laboratories, Physician Laboratories, Academic and Research Centers, Others); By Region (U.S., Canada, Mexico, Rest of North America, France, UK, Germany, Spain, Italy, Nordic Countries, Benelux Union, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Rest of Asia Pacific, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of MEA, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030
Industry Trends
Global liquid biopsy products market is expected to reach US$ 18.5 Bn by 2030, growing at an estimated CAGR of 20% over the forecast period. Fluid biopsy or fluid phase biopsy, more commonly known as liquid biopsy basically happens to be sampling and analysis of biological tissue that is non-solid, mainly blood. Similar to conventional biopsy, this type of test/ method is basically used as a diagnostic and monitoring tool for dreadful ailments like cancer. This technique is non-invasive and this is what gives it an edge when it comes to diagnose cancer. Liquid biopsies are more likely to be used to grant validation to the efficacy of any type of cancer treatment drug by testing various samples within the period of few weeks. Owing to multiple factors, the global liquid biopsy products market is exponentially growing.
The COVID-19 pandemic positively impacted the growth of the global liquid biopsy products market. Higher prevalence of dreadful infection in people with co-morbidities or any life-threatening disease like cancer helped this market grow.
By Application
On the basis of application, the global liquid biopsy products market has been bifurcated into circulating tumor cells (CTC) in the blood, cell free DNA from tumor or fetus cells (in the blood), molecular diagnostics, early-stage cancer, non-invasive prenatal tests (NIPT) and others. The early-stage cancer segment has been further categorised into lung cancer, breast cancer, colorectal cancer, gastric cancer, prostate cancer, liver cancer, bladder cancer, ovarian cancer and others. Rising prevalence of cancer in people across the globe, especially those aging below thirty is the reason why this segment accounts for majority of revenue generated by this market.
Global Liquid Biopsy Products Market Revenue & Forecast, (US$ Million), 2022 – 2030
By Size
The size segment of the global liquid biopsy products market has been bifurcated into 5 ml, 50 ml, 100 ml, 250 ml, and above 250 ml. The 250 ml segment mints major chunk of money for this market as this sample size tests blood and tissue. This helps determine efficacy of the treatment in the quickest way and hence preferred the most by the medical experts across the globe.
By Offering
On the basis of offering, the global liquid biopsy products market has been divided into instruments, reagents, liquid biopsy assays, tools, services and others. The instruments segment is further segmented into blood collection tube (BCT) for cfDNA and CTCs, target selector kits, cell free DNA extraction kit, cell free nucleic acid extraction kit, mutation quantification control plasma, genomic profiling diagnostic kit, target selector NGS panels, PCR purification kit, blood nucleic acid extraction, viral nucleic acid extraction, and others. On the other hand, the services segment is further categorised into custom services and support services. The instrument segments most of the money for this market. These instruments are utterly important in conducting this biopsy.
By End User
On the basis of the end user, the global liquid biopsy products market has been segmented into hospitals/ clinics, pathology laboratories, physician laboratories, academic and research centers, and others. Pathology labs are truly the number one choice of people who want to get fluid biopsy done and this is the reason why the segment makes majority of money for this market.
Region Outlook
On the basis of region, the global liquid biopsy products market has been divided into Latin America, Europe, North America, Asia-Pacific and others. The region of North America ranks number one in terms of accumulating money for this market. Higher awareness among patients and advanced healthcare infrastructure in the countries like the United States and Canada helps this market grow here.
Competitive Landscape
The report provides both, qualitative and quantitative research of global liquid biopsy products market as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contacts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the major players operating in the global liquid biopsy products market are listed below:
- Biocept, Inc.
- BioChain Institute Inc.
- Bio-Rad Laboratories, Inc.
- Hoffmann-La Roche Ltd
- Genomic Health
- Grail Bio, an Illumina spinoff
- Guardant Health
- MDxHealth
- Pathway Genomics
- Personal Genome Diagnostics Inc.
- QIAGEN
- Other Market Participants
Global Liquid Biopsy Products Market
By Application
- Circulating tumor cells (CTC) in the blood
- Cell free DNA from tumor or fetus cells (in the blood)
- Molecular Diagnostics
- Early Stage Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Gastric Cancer
- Prostate Cancer
- Liver Cancer
- Bladder Cancer
- Ovarian Cancer
- Others
- Non-invasive prenatal tests (NIPT)
- Others
By Size
- 5 ml
- 50 ml
- 100 ml
- 250 ml
- Above 250 ml
By Offering
- Instruments
- Blood Collection Tube (BCT) for cfDNA and CTCs
- Target Selector Kits
- Cell Free DNA Extraction Kit
- Cell Free Nucleic Acid Extraction Kit
- Mutation Quantification Control Plasma
- Genomic profiling diagnostic kit
- Target Selector NGS Panels
- PCR Purification Kit
- Blood Nucleic Acid Extraction
- Viral Nucleic Acid Extraction
- Others
- Reagents
- Liquid Biopsy Assays
- Tools
- Services
- Custom Services
- Support Services
- Others
By End User
- Hospitals/ Clinics
- Pathology Laboratories
- Physician Laboratories
- Academic and Research Centers
- Others
By Region
- North America
- U.S
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1. Market
Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2015 - 2020
1.2.2. Base
Year: 2021
1.2.3. Forecast
Years: 2022 – 2030
2. Key Target
Audiences
3. Research
Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations
and Insights from AMI’s Perspective**
5. Holistic
Overview of Liquid Biopsy Products Market
6. Market
Synopsis: Liquid Biopsy Products Market
7. Liquid
Biopsy Products Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Liquid Biopsy Products Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Liquid Biopsy Products Market
7.6. Porter’s
Five Force Analysis
7.7. Impact of
Covid-19 on Liquid Biopsy Products Market
8. Global
Liquid Biopsy Products Market Analysis and Forecasts, 2022 – 2030
8.1. Overview
8.1.1. Global
Liquid Biopsy Products Market Revenue (US$ Mn)
8.2. Global
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application
8.2.1. Circulating
Tumor Cells (CTC) in the Blood
8.2.1.1. Definition
8.2.1.2. Market
Estimation and Penetration, 2015 – 2021
8.2.1.3. Market
Forecast, 2022 – 2030
8.2.1.4. Compound
Annual Growth Rate (CAGR)
8.2.1.5. Regional
Bifurcation
8.2.1.5.1. North
America
8.2.1.5.1.1. Market
Estimation, 2015 – 2021
8.2.1.5.1.2. Market
Forecast, 2022 – 2030
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2015 – 2021
8.2.1.5.2.2. Market
Forecast, 2022 – 2030
8.2.1.5.3. Asia
Pacific
8.2.1.5.3.1. Market
Estimation, 2015 – 2021
8.2.1.5.3.2. Market
Forecast, 2022 – 2030
8.2.1.5.4. Middle
East and Africa
8.2.1.5.4.1. Market
Estimation, 2015 – 2021
8.2.1.5.4.2. Market
Forecast, 2022 – 2030
8.2.1.5.5. Latin
America
8.2.1.5.5.1. Market
Estimation, 2015 – 2021
8.2.1.5.5.2. Market
Forecast, 2022 – 2030
8.2.2. Cell
Free DNA from Tumor or Fetus Cells (in the blood)
8.2.2.1. Definition
8.2.2.2. Market
Estimation and Penetration, 2015 – 2021
8.2.2.3. Market
Forecast, 2022 – 2030
8.2.2.4. Compound
Annual Growth Rate (CAGR)
8.2.2.5. Regional
Bifurcation
8.2.2.5.1. North
America
8.2.2.5.1.1. Market
Estimation, 2015 – 2021
8.2.2.5.1.2. Market
Forecast, 2022 – 2030
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2015 – 2021
8.2.2.5.2.2. Market
Forecast, 2022 – 2030
8.2.2.5.3. Asia
Pacific
8.2.2.5.3.1. Market
Estimation, 2015 – 2021
8.2.2.5.3.2. Market
Forecast, 2022 – 2030
8.2.2.5.4. Middle
East and Africa
8.2.2.5.4.1. Market
Estimation, 2015 – 2021
8.2.2.5.4.2. Market
Forecast, 2022 – 2030
8.2.2.5.5. Latin
America
8.2.2.5.5.1. Market
Estimation, 2015 – 2021
8.2.2.5.5.2. Market
Forecast, 2022 – 2030
8.2.3. Molecular
Diagnostics
8.2.3.1. Definition
8.2.3.2. Market
Estimation and Penetration, 2015 – 2021
8.2.3.3. Market
Forecast, 2022 – 2030
8.2.3.4. Compound
Annual Growth Rate (CAGR)
8.2.3.5. Regional
Bifurcation
8.2.3.5.1. North
America
8.2.3.5.1.1. Market
Estimation, 2015 – 2021
8.2.3.5.1.2. Market
Forecast, 2022 – 2030
8.2.3.5.2. Europe
8.2.3.5.2.1. Market
Estimation, 2015 – 2021
8.2.3.5.2.2. Market
Forecast, 2022 – 2030
8.2.3.5.3. Asia
Pacific
8.2.3.5.3.1. Market
Estimation, 2015 – 2021
8.2.3.5.3.2. Market
Forecast, 2022 – 2030
8.2.3.5.4. Middle
East and Africa
8.2.3.5.4.1. Market
Estimation, 2015 – 2021
8.2.3.5.4.2. Market
Forecast, 2022 – 2030
8.2.3.5.5. Latin
America
8.2.3.5.5.1. Market
Estimation, 2015 – 2021
8.2.3.5.5.2. Market
Forecast, 2022 – 2030
8.2.4. Early
Stage Cancer (Definition, Market Estimation and Penetration, 2015 – 2021,
Market Estimation (2015 – 2021), Market Forecast (2022 – 2030), Compound Annual
Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific,
Middle East and Africa, Latin America) and Information on Lung Cancer, Breast
Cancer, Colorectal Cancer, Gastric Cancer, Prostate Cancer, Liver Cancer,
Bladder Cancer, Ovarian Cancer, Others)
8.2.4.1. Lung
Cancer
8.2.4.2. Breast
Cancer
8.2.4.3. Colorectal
Cancer
8.2.4.4. Gastric
Cancer
8.2.4.5. Prostate
Cancer
8.2.4.6. Liver
Cancer
8.2.4.7. Bladder
Cancer
8.2.4.8. Ovarian
Cancer
8.2.4.9. Others
8.2.5. Non-invasive
Prenatal Tests (NIPT)
8.2.5.1. Definition
8.2.5.2. Market
Estimation and Penetration, 2015 – 2021
8.2.5.3. Market
Forecast, 2022 – 2030
8.2.5.4. Compound
Annual Growth Rate (CAGR)
8.2.5.5. Regional
Bifurcation
8.2.5.5.1. North
America
8.2.5.5.1.1. Market
Estimation, 2015 – 2021
8.2.5.5.1.2. Market
Forecast, 2022 – 2030
8.2.5.5.2. Europe
8.2.5.5.2.1. Market
Estimation, 2015 – 2021
8.2.5.5.2.2. Market
Forecast, 2022 – 2030
8.2.5.5.3. Asia
Pacific
8.2.5.5.3.1. Market
Estimation, 2015 – 2021
8.2.5.5.3.2. Market
Forecast, 2022 – 2030
8.2.5.5.4. Middle
East and Africa
8.2.5.5.4.1. Market
Estimation, 2015 – 2021
8.2.5.5.4.2. Market
Forecast, 2022 – 2030
8.2.5.5.5. Latin
America
8.2.5.5.5.1. Market
Estimation, 2015 – 2021
8.2.5.5.5.2. Market
Forecast, 2022 – 2030
8.2.6. Others
8.2.6.1. Definition
8.2.6.2. Market
Estimation and Penetration, 2015 – 2021
8.2.6.3. Market
Forecast, 2022 – 2030
8.2.6.4. Compound
Annual Growth Rate (CAGR)
8.2.6.5. Regional
Bifurcation
8.2.6.5.1. North
America
8.2.6.5.1.1. Market
Estimation, 2015 – 2021
8.2.6.5.1.2. Market
Forecast, 2022 – 2030
8.2.6.5.2. Europe
8.2.6.5.2.1. Market
Estimation, 2015 – 2021
8.2.6.5.2.2. Market
Forecast, 2022 – 2030
8.2.6.5.3. Asia
Pacific
8.2.6.5.3.1. Market
Estimation, 2015 – 2021
8.2.6.5.3.2. Market
Forecast, 2022 – 2030
8.2.6.5.4. Middle
East and Africa
8.2.6.5.4.1. Market
Estimation, 2015 – 2021
8.2.6.5.4.2. Market
Forecast, 2022 – 2030
8.2.6.5.5. Latin
America
8.2.6.5.5.1. Market
Estimation, 2015 – 2021
8.2.6.5.5.2. Market
Forecast, 2022 – 2030
8.3. Key
Segment for Channeling Investments
8.3.1. By
Application
9. Global
Liquid Biopsy Products Market Analysis and Forecasts, 2022 – 2030
9.1. Overview
9.2. Global
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size
9.2.1. 5 ml
9.2.1.1. Definition
9.2.1.2. Market
Estimation and Penetration, 2015 – 2021
9.2.1.3. Market
Forecast, 2022 – 2030
9.2.1.4. Compound
Annual Growth Rate (CAGR)
9.2.1.5. Regional
Bifurcation
9.2.1.5.1. North
America
9.2.1.5.1.1. Market
Estimation, 2015 – 2021
9.2.1.5.1.2. Market
Forecast, 2022 – 2030
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2015 – 2021
9.2.1.5.2.2. Market
Forecast, 2022 – 2030
9.2.1.5.3. Asia
Pacific
9.2.1.5.3.1. Market
Estimation, 2015 – 2021
9.2.1.5.3.2. Market
Forecast, 2022 – 2030
9.2.1.5.4. Middle
East and Africa
9.2.1.5.4.1. Market
Estimation, 2015 – 2021
9.2.1.5.4.2. Market
Forecast, 2022 – 2030
9.2.1.5.5. Latin
America
9.2.1.5.5.1. Market
Estimation, 2015 – 2021
9.2.1.5.5.2. Market
Forecast, 2022 – 2030
9.2.2. 50 ml
9.2.2.1. Definition
9.2.2.2. Market
Estimation and Penetration, 2015 – 2021
9.2.2.3. Market
Forecast, 2022 – 2030
9.2.2.4. Compound
Annual Growth Rate (CAGR)
9.2.2.5. Regional
Bifurcation
9.2.2.5.1. North
America
9.2.2.5.1.1. Market
Estimation, 2015 – 2021
9.2.2.5.1.2. Market
Forecast, 2022 – 2030
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2015 – 2021
9.2.2.5.2.2. Market
Forecast, 2022 – 2030
9.2.2.5.3. Asia
Pacific
9.2.2.5.3.1. Market
Estimation, 2015 – 2021
9.2.2.5.3.2. Market
Forecast, 2022 – 2030
9.2.2.5.4. Middle
East and Africa
9.2.2.5.4.1. Market
Estimation, 2015 – 2021
9.2.2.5.4.2. Market
Forecast, 2022 – 2030
9.2.2.5.5. Latin
America
9.2.2.5.5.1. Market
Estimation, 2015 – 2021
9.2.2.5.5.2. Market
Forecast, 2022 – 2030
9.2.3. 100 ml
9.2.3.1. Definition
9.2.3.2. Market
Estimation and Penetration, 2015 – 2021
9.2.3.3. Market
Forecast, 2022 – 2030
9.2.3.4. Compound
Annual Growth Rate (CAGR)
9.2.3.5. Regional
Bifurcation
9.2.3.5.1. North
America
9.2.3.5.1.1. Market
Estimation, 2015 – 2021
9.2.3.5.1.2. Market
Forecast, 2022 – 2030
9.2.3.5.2. Europe
9.2.3.5.2.1. Market
Estimation, 2015 – 2021
9.2.3.5.2.2. Market
Forecast, 2022 – 2030
9.2.3.5.3. Asia
Pacific
9.2.3.5.3.1. Market
Estimation, 2015 – 2021
9.2.3.5.3.2. Market
Forecast, 2022 – 2030
9.2.3.5.4. Middle
East and Africa
9.2.3.5.4.1. Market
Estimation, 2015 – 2021
9.2.3.5.4.2. Market
Forecast, 2022 – 2030
9.2.3.5.5. Latin
America
9.2.3.5.5.1. Market
Estimation, 2015 – 2021
9.2.3.5.5.2. Market
Forecast, 2022 – 2030
9.2.4. 250 ml
9.2.4.1. Definition
9.2.4.2. Market
Estimation and Penetration, 2015 – 2021
9.2.4.3. Market
Forecast, 2022 – 2030
9.2.4.4. Compound
Annual Growth Rate (CAGR)
9.2.4.5. Regional
Bifurcation
9.2.4.5.1. North
America
9.2.4.5.1.1. Market
Estimation, 2015 – 2021
9.2.4.5.1.2. Market
Forecast, 2022 – 2030
9.2.4.5.2. Europe
9.2.4.5.2.1. Market
Estimation, 2015 – 2021
9.2.4.5.2.2. Market
Forecast, 2022 – 2030
9.2.4.5.3. Asia
Pacific
9.2.4.5.3.1. Market
Estimation, 2015 – 2021
9.2.4.5.3.2. Market
Forecast, 2022 – 2030
9.2.4.5.4. Middle
East and Africa
9.2.4.5.4.1. Market
Estimation, 2015 – 2021
9.2.4.5.4.2. Market
Forecast, 2022 – 2030
9.2.4.5.5. Latin
America
9.2.4.5.5.1. Market
Estimation, 2015 – 2021
9.2.4.5.5.2. Market
Forecast, 2022 – 2030
9.2.5. Above
250 ml
9.2.5.1. Definition
9.2.5.2. Market
Estimation and Penetration, 2015 – 2021
9.2.5.3. Market
Forecast, 2022 – 2030
9.2.5.4. Compound
Annual Growth Rate (CAGR)
9.2.5.5. Regional
Bifurcation
9.2.5.5.1. North
America
9.2.5.5.1.1. Market
Estimation, 2015 – 2021
9.2.5.5.1.2. Market
Forecast, 2022 – 2030
9.2.5.5.2. Europe
9.2.5.5.2.1. Market
Estimation, 2015 – 2021
9.2.5.5.2.2. Market
Forecast, 2022 – 2030
9.2.5.5.3. Asia
Pacific
9.2.5.5.3.1. Market
Estimation, 2015 – 2021
9.2.5.5.3.2. Market
Forecast, 2022 – 2030
9.2.5.5.4. Middle
East and Africa
9.2.5.5.4.1. Market
Estimation, 2015 – 2021
9.2.5.5.4.2. Market
Forecast, 2022 – 2030
9.2.5.5.5. Latin
America
9.2.5.5.5.1. Market
Estimation, 2015 – 2021
9.2.5.5.5.2. Market
Forecast, 2022 – 2030
9.3. Key
Segment for Channeling Investments
9.3.1. By Size
10. Global
Liquid Biopsy Products Market Analysis and Forecasts, 2022 – 2030
10.1. Overview
10.2. Global
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering
10.2.1. Instruments
(Definition, Market Estimation and Penetration, 2015 – 2021, Market Estimation
(2015 – 2021), Market Forecast (2022 – 2030), Compound Annual Growth Rate
(CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East
and Africa, Latin America) and Information on Blood Collection Tube (BCT) for
cfDNA and CTCs, Target Selector Kits, Cell Free DNA Extraction Kit, Cell Free
Nucleic Acid Extraction Kit, Mutation Quantification Control Plasma, Genomic
Profiling Diagnostics kit, Target Selector NGS Panels, PCR Purification Kit,
Blood Nucleic Acid Extraction, Viral Nucleic Acid Extraction, Others)
10.2.1.1. Blood
Collection Tube (BCT) for cfDNA and CTCs
10.2.1.2. Target
Selector Kits
10.2.1.3. Cell
Free DNA Extraction Kit
10.2.1.4. Cell
Free Nucleic Acid Extraction Kit
10.2.1.5. Mutation
Quantification Control Plasma
10.2.1.6. Genomic
Profiling Diagnostics kit
10.2.1.7. Target
Selector NGS Panels
10.2.1.8. PCR
Purification Kit
10.2.1.9. Blood
Nucleic Acid Extraction
10.2.1.10. Viral
Nucleic Acid Extraction
10.2.1.11. Others
10.2.2. Reagents
10.2.2.1. Definition
10.2.2.2. Market
Estimation and Penetration, 2015 – 2021
10.2.2.3. Market
Forecast, 2022 – 2030
10.2.2.4. Compound
Annual Growth Rate (CAGR)
10.2.2.5. Regional
Bifurcation
10.2.2.5.1. North
America
10.2.2.5.1.1. Market
Estimation, 2015 – 2021
10.2.2.5.1.2. Market
Forecast, 2022 – 2030
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2015 – 2021
10.2.2.5.2.2. Market
Forecast, 2022 – 2030
10.2.2.5.3. Asia
Pacific
10.2.2.5.3.1. Market
Estimation, 2015 – 2021
10.2.2.5.3.2. Market
Forecast, 2022 – 2030
10.2.2.5.4. Middle
East and Africa
10.2.2.5.4.1. Market
Estimation, 2015 – 2021
10.2.2.5.4.2. Market
Forecast, 2022 – 2030
10.2.2.5.5. Latin
America
10.2.2.5.5.1. Market
Estimation, 2015 – 2021
10.2.2.5.5.2. Market
Forecast, 2022 – 2030
10.2.3. Liquid
Biopsy Assays
10.2.3.1. Definition
10.2.3.2. Market
Estimation and Penetration, 2015 – 2021
10.2.3.3. Market
Forecast, 2022 – 2030
10.2.3.4. Compound
Annual Growth Rate (CAGR)
10.2.3.5. Regional
Bifurcation
10.2.3.5.1. North
America
10.2.3.5.1.1. Market
Estimation, 2015 – 2021
10.2.3.5.1.2. Market
Forecast, 2022 – 2030
10.2.3.5.2. Europe
10.2.3.5.2.1. Market
Estimation, 2015 – 2021
10.2.3.5.2.2. Market
Forecast, 2022 – 2030
10.2.3.5.3. Asia
Pacific
10.2.3.5.3.1. Market
Estimation, 2015 – 2021
10.2.3.5.3.2. Market
Forecast, 2022 – 2030
10.2.3.5.4. Middle
East and Africa
10.2.3.5.4.1. Market
Estimation, 2015 – 2021
10.2.3.5.4.2. Market
Forecast, 2022 – 2030
10.2.3.5.5. Latin
America
10.2.3.5.5.1. Market
Estimation, 2015 – 2021
10.2.3.5.5.2. Market
Forecast, 2022 – 2030
10.2.4. Tools
10.2.4.1. Definition
10.2.4.2. Market
Estimation and Penetration, 2015 – 2021
10.2.4.3. Market
Forecast, 2022 – 2030
10.2.4.4. Compound
Annual Growth Rate (CAGR)
10.2.4.5. Regional
Bifurcation
10.2.4.5.1. North
America
10.2.4.5.1.1. Market
Estimation, 2015 – 2021
10.2.4.5.1.2. Market
Forecast, 2022 – 2030
10.2.4.5.2. Europe
10.2.4.5.2.1. Market
Estimation, 2015 – 2021
10.2.4.5.2.2. Market
Forecast, 2022 – 2030
10.2.4.5.3. Asia
Pacific
10.2.4.5.3.1. Market
Estimation, 2015 – 2021
10.2.4.5.3.2. Market
Forecast, 2022 – 2030
10.2.4.5.4. Middle
East and Africa
10.2.4.5.4.1. Market
Estimation, 2015 – 2021
10.2.4.5.4.2. Market
Forecast, 2022 – 2030
10.2.4.5.5. Latin
America
10.2.4.5.5.1. Market
Estimation, 2015 – 2021
10.2.4.5.5.2. Market
Forecast, 2022 – 2030
10.2.5. Services
(Definition, Market Estimation and Penetration, 2015 – 2021, Market Estimation
(2015 – 2021), Market Forecast (2022 – 2030), Compound Annual Growth Rate
(CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East
and Africa, Latin America) and Information on Custom Services, Support
Services)
10.2.5.1. Custom
Services
10.2.5.2. Support
Services
10.2.6. Others
10.2.6.1. Definition
10.2.6.2. Market
Estimation and Penetration, 2015 – 2021
10.2.6.3. Market
Forecast, 2022 – 2030
10.2.6.4. Compound
Annual Growth Rate (CAGR)
10.2.6.5. Regional
Bifurcation
10.2.6.5.1. North
America
10.2.6.5.1.1. Market
Estimation, 2015 – 2021
10.2.6.5.1.2. Market
Forecast, 2022 – 2030
10.2.6.5.2. Europe
10.2.6.5.2.1. Market
Estimation, 2015 – 2021
10.2.6.5.2.2. Market
Forecast, 2022 – 2030
10.2.6.5.3. Asia
Pacific
10.2.6.5.3.1. Market
Estimation, 2015 – 2021
10.2.6.5.3.2. Market
Forecast, 2022 – 2030
10.2.6.5.4. Middle
East and Africa
10.2.6.5.4.1. Market
Estimation, 2015 – 2021
10.2.6.5.4.2. Market
Forecast, 2022 – 2030
10.2.6.5.5. Latin
America
10.2.6.5.5.1. Market
Estimation, 2015 – 2021
10.2.6.5.5.2. Market
Forecast, 2022 – 2030
10.3. Key
Segment for Channeling Investments
10.3.1. By
Offering
11. Global
Liquid Biopsy Products Market Analysis and Forecasts, 2022 – 2030
11.1. Overview
11.2. Global
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User
11.2.1. Hospitals/Clinics
11.2.1.1. Definition
11.2.1.2. Market
Estimation and Penetration, 2015 – 2021
11.2.1.3. Market
Forecast, 2022 – 2030
11.2.1.4. Compound
Annual Growth Rate (CAGR)
11.2.1.5. Regional
Bifurcation
11.2.1.5.1. North
America
11.2.1.5.1.1. Market
Estimation, 2015 – 2021
11.2.1.5.1.2. Market
Forecast, 2022 – 2030
11.2.1.5.2. Europe
11.2.1.5.2.1. Market
Estimation, 2015 – 2021
11.2.1.5.2.2. Market
Forecast, 2022 – 2030
11.2.1.5.3. Asia
Pacific
11.2.1.5.3.1. Market
Estimation, 2015 – 2021
11.2.1.5.3.2. Market
Forecast, 2022 – 2030
11.2.1.5.4. Middle
East and Africa
11.2.1.5.4.1. Market
Estimation, 2015 – 2021
11.2.1.5.4.2. Market
Forecast, 2022 – 2030
11.2.1.5.5. Latin
America
11.2.1.5.5.1. Market
Estimation, 2015 – 2021
11.2.1.5.5.2. Market
Forecast, 2022 – 2030
11.2.2. Pathology
Laboratories
11.2.2.1. Definition
11.2.2.2. Market
Estimation and Penetration, 2015 – 2021
11.2.2.3. Market
Forecast, 2022 – 2030
11.2.2.4. Compound
Annual Growth Rate (CAGR)
11.2.2.5. Regional
Bifurcation
11.2.2.5.1. North
America
11.2.2.5.1.1. Market
Estimation, 2015 – 2021
11.2.2.5.1.2. Market
Forecast, 2022 – 2030
11.2.2.5.2. Europe
11.2.2.5.2.1. Market
Estimation, 2015 – 2021
11.2.2.5.2.2. Market
Forecast, 2022 – 2030
11.2.2.5.3. Asia
Pacific
11.2.2.5.3.1. Market
Estimation, 2015 – 2021
11.2.2.5.3.2. Market
Forecast, 2022 – 2030
11.2.2.5.4. Middle
East and Africa
11.2.2.5.4.1. Market
Estimation, 2015 – 2021
11.2.2.5.4.2. Market
Forecast, 2022 – 2030
11.2.2.5.5. Latin
America
11.2.2.5.5.1. Market
Estimation, 2015 – 2021
11.2.2.5.5.2. Market
Forecast, 2022 – 2030
11.2.3. Physician
Laboratories
11.2.3.1. Definition
11.2.3.2. Market
Estimation and Penetration, 2015 – 2021
11.2.3.3. Market
Forecast, 2022 – 2030
11.2.3.4. Compound
Annual Growth Rate (CAGR)
11.2.3.5. Regional
Bifurcation
11.2.3.5.1. North
America
11.2.3.5.1.1. Market
Estimation, 2015 – 2021
11.2.3.5.1.2. Market
Forecast, 2022 – 2030
11.2.3.5.2. Europe
11.2.3.5.2.1. Market
Estimation, 2015 – 2021
11.2.3.5.2.2. Market
Forecast, 2022 – 2030
11.2.3.5.3. Asia
Pacific
11.2.3.5.3.1. Market
Estimation, 2015 – 2021
11.2.3.5.3.2. Market
Forecast, 2022 – 2030
11.2.3.5.4. Middle
East and Africa
11.2.3.5.4.1. Market
Estimation, 2015 – 2021
11.2.3.5.4.2. Market
Forecast, 2022 – 2030
11.2.3.5.5. Latin
America
11.2.3.5.5.1. Market
Estimation, 2015 – 2021
11.2.3.5.5.2. Market
Forecast, 2022 – 2030
11.2.4. Academic
and Research Centers
11.2.4.1. Definition
11.2.4.2. Market
Estimation and Penetration, 2015 – 2021
11.2.4.3. Market
Forecast, 2022 – 2030
11.2.4.4. Compound
Annual Growth Rate (CAGR)
11.2.4.5. Regional
Bifurcation
11.2.4.5.1. North
America
11.2.4.5.1.1. Market
Estimation, 2015 – 2021
11.2.4.5.1.2. Market
Forecast, 2022 – 2030
11.2.4.5.2. Europe
11.2.4.5.2.1. Market
Estimation, 2015 – 2021
11.2.4.5.2.2. Market
Forecast, 2022 – 2030
11.2.4.5.3. Asia
Pacific
11.2.4.5.3.1. Market
Estimation, 2015 – 2021
11.2.4.5.3.2. Market
Forecast, 2022 – 2030
11.2.4.5.4. Middle
East and Africa
11.2.4.5.4.1. Market
Estimation, 2015 – 2021
11.2.4.5.4.2. Market
Forecast, 2022 – 2030
11.2.4.5.5. Latin
America
11.2.4.5.5.1. Market
Estimation, 2015 – 2021
11.2.4.5.5.2. Market
Forecast, 2022 – 2030
11.2.5. Others
11.2.5.1. Definition
11.2.5.2. Market
Estimation and Penetration, 2015 – 2021
11.2.5.3. Market
Forecast, 2022 – 2030
11.2.5.4. Compound
Annual Growth Rate (CAGR)
11.2.5.5. Regional
Bifurcation
11.2.5.5.1. North
America
11.2.5.5.1.1. Market
Estimation, 2015 – 2021
11.2.5.5.1.2. Market
Forecast, 2022 – 2030
11.2.5.5.2. Europe
11.2.5.5.2.1. Market
Estimation, 2015 – 2021
11.2.5.5.2.2. Market
Forecast, 2022 – 2030
11.2.5.5.3. Asia
Pacific
11.2.5.5.3.1. Market
Estimation, 2015 – 2021
11.2.5.5.3.2. Market
Forecast, 2022 – 2030
11.2.5.5.4. Middle
East and Africa
11.2.5.5.4.1. Market
Estimation, 2015 – 2021
11.2.5.5.4.2. Market
Forecast, 2022 – 2030
11.2.5.5.5. Latin
America
11.2.5.5.5.1. Market
Estimation, 2015 – 2021
11.2.5.5.5.2. Market
Forecast, 2022 – 2030
11.3. Key
Segment for Channeling Investments
11.3.1. By End
User
12. North
America Liquid Biopsy Products Market Analysis and Forecasts, 2022 – 2030
12.1. Overview
12.1.1. North
America Liquid Biopsy Products Market Revenue (US$ Mn)
12.2. North
America Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By
Application
12.2.1. Circulating
Tumor Cells (CTC) in the Blood
12.2.2. Cell
Free DNA from Tumor or Fetus Cells (in the blood)
12.2.3. Molecular
Diagnostics
12.2.4. Early
Stage Cancer
12.2.4.1. Lung
Cancer
12.2.4.2. Breast
Cancer
12.2.4.3. Colorectal
Cancer
12.2.4.4. Gastric
Cancer
12.2.4.5. Prostate
Cancer
12.2.4.6. Liver
Cancer
12.2.4.7. Bladder
Cancer
12.2.4.8. Ovarian
Cancer
12.2.4.9. Others
12.2.5. Non-invasive
Prenatal Tests (NIPT)
12.2.6. Others
12.3. North
America Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size
12.3.1. 5 ml
12.3.2. 50 ml
12.3.3. 100 ml
12.3.4. 250 ml
12.3.5. Above
250 ml
12.4. North
America Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By
Offering
12.4.1. Instruments
12.4.1.1. Blood
Collection Tube (BCT) for cfDNA and CTCs
12.4.1.2. Target
Selector Kits
12.4.1.3. Cell
Free DNA Extraction Kit
12.4.1.4. Cell
Free Nucleic Acid Extraction Kit
12.4.1.5. Mutation
Quantification Control Plasma
12.4.1.6. Genomic
Profiling Diagnostics kit
12.4.1.7. Target
Selector NGS Panels
12.4.1.8. PCR
Purification Kit
12.4.1.9. Blood
Nucleic Acid Extraction
12.4.1.10. Viral
Nucleic Acid Extraction
12.4.1.11. Others
12.4.2. Reagents
12.4.3. Liquid
Biopsy Assays
12.4.4. Tools
12.4.5. Services
12.4.5.1. Custom
Services
12.4.5.2. Support
Services
12.4.6. Others
12.5. North
America Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End
User
12.5.1. Hospitals/Clinics
12.5.2. Pathology
Laboratories
12.5.3. Physician
Laboratories
12.5.4. Academic
and Research Centers
12.5.5. Others
12.6. North
America Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By
Country
12.6.1. U.S
12.6.1.1. U.S
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application
12.6.1.1.1. Circulating
Tumor Cells (CTC) in the Blood
12.6.1.1.2. Cell
Free DNA from Tumor or Fetus Cells (in the blood)
12.6.1.1.3. Molecular
Diagnostics
12.6.1.1.4. Early
Stage Cancer
12.6.1.1.4.1. Lung
Cancer
12.6.1.1.4.2. Breast
Cancer
12.6.1.1.4.3. Colorectal
Cancer
12.6.1.1.4.4. Gastric
Cancer
12.6.1.1.4.5. Prostate
Cancer
12.6.1.1.4.6. Liver
Cancer
12.6.1.1.4.7. Bladder
Cancer
12.6.1.1.4.8. Ovarian
Cancer
12.6.1.1.4.9. Others
12.6.1.1.5. Non-invasive
Prenatal Tests (NIPT)
12.6.1.1.6. Others
12.6.1.2. U.S
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size
12.6.1.2.1. 5
ml
12.6.1.2.2. 50
ml
12.6.1.2.3. 100
ml
12.6.1.2.4. 250
ml
12.6.1.2.5. Above
250 ml
12.6.1.3. U.S
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering
12.6.1.3.1. Instruments
12.6.1.3.1.1. Blood
Collection Tube (BCT) for cfDNA and CTCs
12.6.1.3.1.2. Target
Selector Kits
12.6.1.3.1.3. Cell
Free DNA Extraction Kit
12.6.1.3.1.4. Cell
Free Nucleic Acid Extraction Kit
12.6.1.3.1.5. Mutation
Quantification Control Plasma
12.6.1.3.1.6. Genomic
Profiling Diagnostics kit
12.6.1.3.1.7. Target
Selector NGS Panels
12.6.1.3.1.8. PCR
Purification Kit
12.6.1.3.1.9. Blood
Nucleic Acid Extraction
12.6.1.3.1.10. Viral
Nucleic Acid Extraction
12.6.1.3.1.11. Others
12.6.1.3.2. Reagents
12.6.1.3.3. Liquid
Biopsy Assays
12.6.1.3.4. Tools
12.6.1.3.5. Services
12.6.1.3.5.1. Custom
Services
12.6.1.3.5.2. Support
Services
12.6.1.3.6. Others
12.6.1.4. U.S
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User
12.6.1.4.1. Hospitals/Clinics
12.6.1.4.2. Pathology
Laboratories
12.6.1.4.3. Physician
Laboratories
12.6.1.4.4. Academic
and Research Centers
12.6.1.4.5. Others
12.6.2. Canada
12.6.2.1. Canada
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application
12.6.2.1.1. Circulating
Tumor Cells (CTC) in the Blood
12.6.2.1.2. Cell
Free DNA from Tumor or Fetus Cells (in the blood)
12.6.2.1.3. Molecular
Diagnostics
12.6.2.1.4. Early
Stage Cancer
12.6.2.1.4.1. Lung
Cancer
12.6.2.1.4.2. Breast
Cancer
12.6.2.1.4.3. Colorectal
Cancer
12.6.2.1.4.4. Gastric
Cancer
12.6.2.1.4.5. Prostate
Cancer
12.6.2.1.4.6. Liver
Cancer
12.6.2.1.4.7. Bladder
Cancer
12.6.2.1.4.8. Ovarian
Cancer
12.6.2.1.4.9. Others
12.6.2.1.5. Non-invasive
Prenatal Tests (NIPT)
12.6.2.1.6. Others
12.6.2.2. Canada
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size
12.6.2.2.1. 5
ml
12.6.2.2.2. 50
ml
12.6.2.2.3. 100
ml
12.6.2.2.4. 250
ml
12.6.2.2.5. Above
250 ml
12.6.2.3. Canada
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering
12.6.2.3.1. Instruments
12.6.2.3.1.1. Blood
Collection Tube (BCT) for cfDNA and CTCs
12.6.2.3.1.2. Target
Selector Kits
12.6.2.3.1.3. Cell
Free DNA Extraction Kit
12.6.2.3.1.4. Cell
Free Nucleic Acid Extraction Kit
12.6.2.3.1.5. Mutation
Quantification Control Plasma
12.6.2.3.1.6. Genomic
Profiling Diagnostics kit
12.6.2.3.1.7. Target
Selector NGS Panels
12.6.2.3.1.8. PCR
Purification Kit
12.6.2.3.1.9. Blood
Nucleic Acid Extraction
12.6.2.3.1.10. Viral
Nucleic Acid Extraction
12.6.2.3.1.11. Others
12.6.2.3.2. Reagents
12.6.2.3.3. Liquid
Biopsy Assays
12.6.2.3.4. Tools
12.6.2.3.5. Services
12.6.2.3.5.1. Custom
Services
12.6.2.3.5.2. Support
Services
12.6.2.3.6. Others
12.6.2.4. Canada
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User
12.6.2.4.1. Hospitals/Clinics
12.6.2.4.2. Pathology
Laboratories
12.6.2.4.3. Physician
Laboratories
12.6.2.4.4. Academic
and Research Centers
12.6.2.4.5. Others
12.6.3. Mexico
12.6.3.1. Mexico
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application
12.6.3.1.1. Circulating
Tumor Cells (CTC) in the Blood
12.6.3.1.2. Cell
Free DNA from Tumor or Fetus Cells (in the blood)
12.6.3.1.3. Molecular
Diagnostics
12.6.3.1.4. Early
Stage Cancer
12.6.3.1.4.1. Lung
Cancer
12.6.3.1.4.2. Breast
Cancer
12.6.3.1.4.3. Colorectal
Cancer
12.6.3.1.4.4. Gastric
Cancer
12.6.3.1.4.5. Prostate
Cancer
12.6.3.1.4.6. Liver
Cancer
12.6.3.1.4.7. Bladder
Cancer
12.6.3.1.4.8. Ovarian
Cancer
12.6.3.1.4.9. Others
12.6.3.1.5. Non-invasive
Prenatal Tests (NIPT)
12.6.3.1.6. Others
12.6.3.2. Mexico
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size
12.6.3.2.1. 5
ml
12.6.3.2.2. 50
ml
12.6.3.2.3. 100
ml
12.6.3.2.4. 250
ml
12.6.3.2.5. Above
250 ml
12.6.3.3. Mexico
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering
12.6.3.3.1. Instruments
12.6.3.3.1.1. Blood
Collection Tube (BCT) for cfDNA and CTCs
12.6.3.3.1.2. Target
Selector Kits
12.6.3.3.1.3. Cell
Free DNA Extraction Kit
12.6.3.3.1.4. Cell
Free Nucleic Acid Extraction Kit
12.6.3.3.1.5. Mutation
Quantification Control Plasma
12.6.3.3.1.6. Genomic
Profiling Diagnostics kit
12.6.3.3.1.7. Target
Selector NGS Panels
12.6.3.3.1.8. PCR
Purification Kit
12.6.3.3.1.9. Blood
Nucleic Acid Extraction
12.6.3.3.1.10. Viral
Nucleic Acid Extraction
12.6.3.3.1.11. Others
12.6.3.3.2. Reagents
12.6.3.3.3. Liquid
Biopsy Assays
12.6.3.3.4. Tools
12.6.3.3.5. Services
12.6.3.3.5.1. Custom
Services
12.6.3.3.5.2. Support
Services
12.6.3.3.6. Others
12.6.3.4. Mexico
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User
12.6.3.4.1. Hospitals/Clinics
12.6.3.4.2. Pathology
Laboratories
12.6.3.4.3. Physician
Laboratories
12.6.3.4.4. Academic
and Research Centers
12.6.3.4.5. Others
12.6.4. Rest of
North America
12.6.4.1. Rest
of North America Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts,
By Application
12.6.4.1.1. Circulating
Tumor Cells (CTC) in the Blood
12.6.4.1.2. Cell
Free DNA from Tumor or Fetus Cells (in the blood)
12.6.4.1.3. Molecular
Diagnostics
12.6.4.1.4. Early
Stage Cancer
12.6.4.1.4.1. Lung
Cancer
12.6.4.1.4.2. Breast
Cancer
12.6.4.1.4.3. Colorectal
Cancer
12.6.4.1.4.4. Gastric
Cancer
12.6.4.1.4.5. Prostate
Cancer
12.6.4.1.4.6. Liver
Cancer
12.6.4.1.4.7. Bladder
Cancer
12.6.4.1.4.8. Ovarian
Cancer
12.6.4.1.4.9. Others
12.6.4.1.5. Non-invasive
Prenatal Tests (NIPT)
12.6.4.1.6. Others
12.6.4.2. Rest
of North America Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts,
By Size
12.6.4.2.1. 5
ml
12.6.4.2.2. 50
ml
12.6.4.2.3. 100
ml
12.6.4.2.4. 250
ml
12.6.4.2.5. Above
250 ml
12.6.4.3. Rest
of North America Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts,
By Offering
12.6.4.3.1. Instruments
12.6.4.3.1.1. Blood
Collection Tube (BCT) for cfDNA and CTCs
12.6.4.3.1.2. Target
Selector Kits
12.6.4.3.1.3. Cell
Free DNA Extraction Kit
12.6.4.3.1.4. Cell
Free Nucleic Acid Extraction Kit
12.6.4.3.1.5. Mutation
Quantification Control Plasma
12.6.4.3.1.6. Genomic
Profiling Diagnostics kit
12.6.4.3.1.7. Target
Selector NGS Panels
12.6.4.3.1.8. PCR
Purification Kit
12.6.4.3.1.9. Blood
Nucleic Acid Extraction
12.6.4.3.1.10. Viral
Nucleic Acid Extraction
12.6.4.3.1.11. Others
12.6.4.3.2. Reagents
12.6.4.3.3. Liquid
Biopsy Assays
12.6.4.3.4. Tools
12.6.4.3.5. Services
12.6.4.3.5.1. Custom
Services
12.6.4.3.5.2. Support
Services
12.6.4.3.6. Others
12.6.4.4. Rest
of North America Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts,
By End User
12.6.4.4.1. Hospitals/Clinics
12.6.4.4.2. Pathology
Laboratories
12.6.4.4.3. Physician
Laboratories
12.6.4.4.4. Academic
and Research Centers
12.6.4.4.5. Others
12.7. Key
Segment for Channeling Investments
12.7.1. By
Country
12.7.2. By
Application
12.7.3. By Size
12.7.4. By
Offering
12.7.5. By End
User
13. Europe
Liquid Biopsy Products Market Analysis and Forecasts, 2022 – 2030
13.1. Overview
13.1.1. Europe
Liquid Biopsy Products Market Revenue (US$ Mn)
13.2. Europe
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application
13.2.1. Circulating
Tumor Cells (CTC) in the Blood
13.2.2. Cell
Free DNA from Tumor or Fetus Cells (in the blood)
13.2.3. Molecular
Diagnostics
13.2.4. Early
Stage Cancer
13.2.4.1. Lung
Cancer
13.2.4.2. Breast
Cancer
13.2.4.3. Colorectal
Cancer
13.2.4.4. Gastric
Cancer
13.2.4.5. Prostate
Cancer
13.2.4.6. Liver
Cancer
13.2.4.7. Bladder
Cancer
13.2.4.8. Ovarian
Cancer
13.2.4.9. Others
13.2.5. Non-invasive
Prenatal Tests (NIPT)
13.2.6. Others
13.3. Europe
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size
13.3.1. 5 ml
13.3.2. 50 ml
13.3.3. 100 ml
13.3.4. 250 ml
13.3.5. Above
250 ml
13.4. Europe
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering
13.4.1. Instruments
13.4.1.1. Blood
Collection Tube (BCT) for cfDNA and CTCs
13.4.1.2. Target
Selector Kits
13.4.1.3. Cell
Free DNA Extraction Kit
13.4.1.4. Cell
Free Nucleic Acid Extraction Kit
13.4.1.5. Mutation
Quantification Control Plasma
13.4.1.6. Genomic
Profiling Diagnostics kit
13.4.1.7. Target
Selector NGS Panels
13.4.1.8. PCR
Purification Kit
13.4.1.9. Blood
Nucleic Acid Extraction
13.4.1.10. Viral
Nucleic Acid Extraction
13.4.1.11. Others
13.4.2. Reagents
13.4.3. Liquid
Biopsy Assays
13.4.4. Tools
13.4.5. Services
13.4.5.1. Custom
Services
13.4.5.2. Support
Services
13.4.6. Others
13.5. Europe
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User
13.5.1. Hospitals/Clinics
13.5.2. Pathology
Laboratories
13.5.3. Physician
Laboratories
13.5.4. Academic
and Research Centers
13.5.5. Others
13.6. Europe
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Country
13.6.1. France
13.6.1.1. France
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application
13.6.1.1.1. Circulating
Tumor Cells (CTC) in the Blood
13.6.1.1.2. Cell
Free DNA from Tumor or Fetus Cells (in the blood)
13.6.1.1.3. Molecular
Diagnostics
13.6.1.1.4. Early
Stage Cancer
13.6.1.1.4.1. Lung
Cancer
13.6.1.1.4.2. Breast
Cancer
13.6.1.1.4.3. Colorectal
Cancer
13.6.1.1.4.4. Gastric
Cancer
13.6.1.1.4.5. Prostate
Cancer
13.6.1.1.4.6. Liver
Cancer
13.6.1.1.4.7. Bladder
Cancer
13.6.1.1.4.8. Ovarian
Cancer
13.6.1.1.4.9. Others
13.6.1.1.5. Non-invasive
Prenatal Tests (NIPT)
13.6.1.1.6. Others
13.6.1.2. France
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size
13.6.1.2.1. 5
ml
13.6.1.2.2. 50
ml
13.6.1.2.3. 100
ml
13.6.1.2.4. 250
ml
13.6.1.2.5. Above
250 ml
13.6.1.3. France
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering
13.6.1.3.1. Instruments
13.6.1.3.1.1. Blood
Collection Tube (BCT) for cfDNA and CTCs
13.6.1.3.1.2. Target
Selector Kits
13.6.1.3.1.3. Cell
Free DNA Extraction Kit
13.6.1.3.1.4. Cell
Free Nucleic Acid Extraction Kit
13.6.1.3.1.5. Mutation
Quantification Control Plasma
13.6.1.3.1.6. Genomic
Profiling Diagnostics kit
13.6.1.3.1.7. Target
Selector NGS Panels
13.6.1.3.1.8. PCR
Purification Kit
13.6.1.3.1.9. Blood
Nucleic Acid Extraction
13.6.1.3.1.10. Viral
Nucleic Acid Extraction
13.6.1.3.1.11. Others
13.6.1.3.2. Reagents
13.6.1.3.3. Liquid
Biopsy Assays
13.6.1.3.4. Tools
13.6.1.3.5. Services
13.6.1.3.5.1. Custom
Services
13.6.1.3.5.2. Support
Services
13.6.1.3.6. Others
13.6.1.4. France
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User
13.6.1.4.1. Hospitals/Clinics
13.6.1.4.2. Pathology
Laboratories
13.6.1.4.3. Physician
Laboratories
13.6.1.4.4. Academic
and Research Centers
13.6.1.4.5. Others
13.6.2. The UK
13.6.2.1. The
UK Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application
13.6.2.1.1. Circulating
Tumor Cells (CTC) in the Blood
13.6.2.1.2. Cell
Free DNA from Tumor or Fetus Cells (in the blood)
13.6.2.1.3. Molecular
Diagnostics
13.6.2.1.4. Early
Stage Cancer
13.6.2.1.4.1. Lung
Cancer
13.6.2.1.4.2. Breast
Cancer
13.6.2.1.4.3. Colorectal
Cancer
13.6.2.1.4.4. Gastric
Cancer
13.6.2.1.4.5. Prostate
Cancer
13.6.2.1.4.6. Liver
Cancer
13.6.2.1.4.7. Bladder
Cancer
13.6.2.1.4.8. Ovarian
Cancer
13.6.2.1.4.9. Others
13.6.2.1.5. Non-invasive
Prenatal Tests (NIPT)
13.6.2.1.6. Others
13.6.2.2. The
UK Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size
13.6.2.2.1. 5
ml
13.6.2.2.2. 50
ml
13.6.2.2.3. 100
ml
13.6.2.2.4. 250
ml
13.6.2.2.5. Above
250 ml
13.6.2.3. The
UK Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering
13.6.2.3.1. Instruments
13.6.2.3.1.1. Blood
Collection Tube (BCT) for cfDNA and CTCs
13.6.2.3.1.2. Target
Selector Kits
13.6.2.3.1.3. Cell
Free DNA Extraction Kit
13.6.2.3.1.4. Cell
Free Nucleic Acid Extraction Kit
13.6.2.3.1.5. Mutation
Quantification Control Plasma
13.6.2.3.1.6. Genomic
Profiling Diagnostics kit
13.6.2.3.1.7. Target
Selector NGS Panels
13.6.2.3.1.8. PCR
Purification Kit
13.6.2.3.1.9. Blood
Nucleic Acid Extraction
13.6.2.3.1.10. Viral
Nucleic Acid Extraction
13.6.2.3.1.11. Others
13.6.2.3.2. Reagents
13.6.2.3.3. Liquid
Biopsy Assays
13.6.2.3.4. Tools
13.6.2.3.5. Services
13.6.2.3.5.1. Custom
Services
13.6.2.3.5.2. Support
Services
13.6.2.3.6. Others
13.6.2.4. The
UK Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User
13.6.2.4.1. Hospitals/Clinics
13.6.2.4.2. Pathology
Laboratories
13.6.2.4.3. Physician
Laboratories
13.6.2.4.4. Academic
and Research Centers
13.6.2.4.5. Others
13.6.3. Spain
13.6.3.1. Spain
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application
13.6.3.1.1. Circulating
Tumor Cells (CTC) in the Blood
13.6.3.1.2. Cell
Free DNA from Tumor or Fetus Cells (in the blood)
13.6.3.1.3. Molecular
Diagnostics
13.6.3.1.4. Early
Stage Cancer
13.6.3.1.4.1. Lung
Cancer
13.6.3.1.4.2. Breast
Cancer
13.6.3.1.4.3. Colorectal
Cancer
13.6.3.1.4.4. Gastric
Cancer
13.6.3.1.4.5. Prostate
Cancer
13.6.3.1.4.6. Liver
Cancer
13.6.3.1.4.7. Bladder
Cancer
13.6.3.1.4.8. Ovarian
Cancer
13.6.3.1.4.9. Others
13.6.3.1.5. Non-invasive
Prenatal Tests (NIPT)
13.6.3.1.6. Others
13.6.3.2. Spain
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size
13.6.3.2.1. 5
ml
13.6.3.2.2. 50
ml
13.6.3.2.3. 100
ml
13.6.3.2.4. 250
ml
13.6.3.2.5. Above
250 ml
13.6.3.3. Spain
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering
13.6.3.3.1. Instruments
13.6.3.3.1.1. Blood
Collection Tube (BCT) for cfDNA and CTCs
13.6.3.3.1.2. Target
Selector Kits
13.6.3.3.1.3. Cell
Free DNA Extraction Kit
13.6.3.3.1.4. Cell
Free Nucleic Acid Extraction Kit
13.6.3.3.1.5. Mutation
Quantification Control Plasma
13.6.3.3.1.6. Genomic
Profiling Diagnostics kit
13.6.3.3.1.7. Target
Selector NGS Panels
13.6.3.3.1.8. PCR
Purification Kit
13.6.3.3.1.9. Blood
Nucleic Acid Extraction
13.6.3.3.1.10. Viral
Nucleic Acid Extraction
13.6.3.3.1.11. Others
13.6.3.3.2. Reagents
13.6.3.3.3. Liquid
Biopsy Assays
13.6.3.3.4. Tools
13.6.3.3.5. Services
13.6.3.3.5.1. Custom
Services
13.6.3.3.5.2. Support
Services
13.6.3.3.6. Others
13.6.3.4. Spain
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User
13.6.3.4.1. Hospitals/Clinics
13.6.3.4.2. Pathology
Laboratories
13.6.3.4.3. Physician
Laboratories
13.6.3.4.4. Academic
and Research Centers
13.6.3.4.5. Others
13.6.4. Germany
13.6.4.1. Germany
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application
13.6.4.1.1. Circulating
Tumor Cells (CTC) in the Blood
13.6.4.1.2. Cell
Free DNA from Tumor or Fetus Cells (in the blood)
13.6.4.1.3. Molecular
Diagnostics
13.6.4.1.4. Early
Stage Cancer
13.6.4.1.4.1. Lung
Cancer
13.6.4.1.4.2. Breast
Cancer
13.6.4.1.4.3. Colorectal
Cancer
13.6.4.1.4.4. Gastric
Cancer
13.6.4.1.4.5. Prostate
Cancer
13.6.4.1.4.6. Liver
Cancer
13.6.4.1.4.7. Bladder
Cancer
13.6.4.1.4.8. Ovarian
Cancer
13.6.4.1.4.9. Others
13.6.4.1.5. Non-invasive
Prenatal Tests (NIPT)
13.6.4.1.6. Others
13.6.4.2. Germany
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size
13.6.4.2.1. 5
ml
13.6.4.2.2. 50
ml
13.6.4.2.3. 100
ml
13.6.4.2.4. 250
ml
13.6.4.2.5. Above
250 ml
13.6.4.3. Germany
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering
13.6.4.3.1. Instruments
13.6.4.3.1.1. Blood
Collection Tube (BCT) for cfDNA and CTCs
13.6.4.3.1.2. Target
Selector Kits
13.6.4.3.1.3. Cell
Free DNA Extraction Kit
13.6.4.3.1.4. Cell
Free Nucleic Acid Extraction Kit
13.6.4.3.1.5. Mutation
Quantification Control Plasma
13.6.4.3.1.6. Genomic
Profiling Diagnostics kit
13.6.4.3.1.7. Target
Selector NGS Panels
13.6.4.3.1.8. PCR
Purification Kit
13.6.4.3.1.9. Blood
Nucleic Acid Extraction
13.6.4.3.1.10. Viral
Nucleic Acid Extraction
13.6.4.3.1.11. Others
13.6.4.3.2. Reagents
13.6.4.3.3. Liquid
Biopsy Assays
13.6.4.3.4. Tools
13.6.4.3.5. Services
13.6.4.3.5.1. Custom
Services
13.6.4.3.5.2. Support
Services
13.6.4.3.6. Others
13.6.4.4. Germany
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User
13.6.4.4.1. Hospitals/Clinics
13.6.4.4.2. Pathology
Laboratories
13.6.4.4.3. Physician
Laboratories
13.6.4.4.4. Academic
and Research Centers
13.6.4.4.5. Others
13.6.5. Italy
13.6.5.1. Italy
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application
13.6.5.1.1. Circulating
Tumor Cells (CTC) in the Blood
13.6.5.1.2. Cell
Free DNA from Tumor or Fetus Cells (in the blood)
13.6.5.1.3. Molecular
Diagnostics
13.6.5.1.4. Early
Stage Cancer
13.6.5.1.4.1. Lung
Cancer
13.6.5.1.4.2. Breast
Cancer
13.6.5.1.4.3. Colorectal
Cancer
13.6.5.1.4.4. Gastric
Cancer
13.6.5.1.4.5. Prostate
Cancer
13.6.5.1.4.6. Liver
Cancer
13.6.5.1.4.7. Bladder
Cancer
13.6.5.1.4.8. Ovarian
Cancer
13.6.5.1.4.9. Others
13.6.5.1.5. Non-invasive
Prenatal Tests (NIPT)
13.6.5.1.6. Others
13.6.5.2. Italy
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size
13.6.5.2.1. 5
ml
13.6.5.2.2. 50
ml
13.6.5.2.3. 100
ml
13.6.5.2.4. 250
ml
13.6.5.2.5. Above
250 ml
13.6.5.3. Italy
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering
13.6.5.3.1. Instruments
13.6.5.3.1.1. Blood
Collection Tube (BCT) for cfDNA and CTCs
13.6.5.3.1.2. Target
Selector Kits
13.6.5.3.1.3. Cell
Free DNA Extraction Kit
13.6.5.3.1.4. Cell
Free Nucleic Acid Extraction Kit
13.6.5.3.1.5. Mutation
Quantification Control Plasma
13.6.5.3.1.6. Genomic
Profiling Diagnostics kit
13.6.5.3.1.7. Target
Selector NGS Panels
13.6.5.3.1.8. PCR
Purification Kit
13.6.5.3.1.9. Blood
Nucleic Acid Extraction
13.6.5.3.1.10. Viral
Nucleic Acid Extraction
13.6.5.3.1.11. Others
13.6.5.3.2. Reagents
13.6.5.3.3. Liquid
Biopsy Assays
13.6.5.3.4. Tools
13.6.5.3.5. Services
13.6.5.3.5.1. Custom
Services
13.6.5.3.5.2. Support
Services
13.6.5.3.6. Others
13.6.5.4. Italy
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User
13.6.5.4.1. Hospitals/Clinics
13.6.5.4.2. Pathology
Laboratories
13.6.5.4.3. Physician
Laboratories
13.6.5.4.4. Academic
and Research Centers
13.6.5.4.5. Others
13.6.6. Nordic
Countries
13.6.6.1. Nordic
Countries Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By
Application
13.6.6.1.1. Circulating
Tumor Cells (CTC) in the Blood
13.6.6.1.2. Cell
Free DNA from Tumor or Fetus Cells (in the blood)
13.6.6.1.3. Molecular
Diagnostics
13.6.6.1.4. Early
Stage Cancer
13.6.6.1.4.1. Lung
Cancer
13.6.6.1.4.2. Breast
Cancer
13.6.6.1.4.3. Colorectal
Cancer
13.6.6.1.4.4. Gastric
Cancer
13.6.6.1.4.5. Prostate
Cancer
13.6.6.1.4.6. Liver
Cancer
13.6.6.1.4.7. Bladder
Cancer
13.6.6.1.4.8. Ovarian
Cancer
13.6.6.1.4.9. Others
13.6.6.1.5. Non-invasive
Prenatal Tests (NIPT)
13.6.6.1.6. Others
13.6.6.2. Nordic
Countries Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size
13.6.6.2.1. 5
ml
13.6.6.2.2. 50
ml
13.6.6.2.3. 100
ml
13.6.6.2.4. 250
ml
13.6.6.2.5. Above
250 ml
13.6.6.3. Nordic
Countries Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By
Offering
13.6.6.3.1. Instruments
13.6.6.3.1.1. Blood
Collection Tube (BCT) for cfDNA and CTCs
13.6.6.3.1.2. Target
Selector Kits
13.6.6.3.1.3. Cell
Free DNA Extraction Kit
13.6.6.3.1.4. Cell
Free Nucleic Acid Extraction Kit
13.6.6.3.1.5. Mutation
Quantification Control Plasma
13.6.6.3.1.6. Genomic
Profiling Diagnostics kit
13.6.6.3.1.7. Target
Selector NGS Panels
13.6.6.3.1.8. PCR
Purification Kit
13.6.6.3.1.9. Blood
Nucleic Acid Extraction
13.6.6.3.1.10. Viral
Nucleic Acid Extraction
13.6.6.3.1.11. Others
13.6.6.3.2. Reagents
13.6.6.3.3. Liquid
Biopsy Assays
13.6.6.3.4. Tools
13.6.6.3.5. Services
13.6.6.3.5.1. Custom
Services
13.6.6.3.5.2. Support
Services
13.6.6.3.6. Others
13.6.6.4. Nordic
Countries Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End
User
13.6.6.4.1. Hospitals/Clinics
13.6.6.4.2. Pathology
Laboratories
13.6.6.4.3. Physician
Laboratories
13.6.6.4.4. Academic
and Research Centers
13.6.6.4.5. Others
13.6.6.5. Nordic
Countries Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By
Country
13.6.6.5.1. Denmark
13.6.6.5.2. Finland
13.6.6.5.3. Iceland
13.6.6.5.4. Sweden
13.6.6.5.5. Norway
13.6.7. Benelux
Union
13.6.7.1. Benelux
Union Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By
Application
13.6.7.1.1. Circulating
Tumor Cells (CTC) in the Blood
13.6.7.1.2. Cell
Free DNA from Tumor or Fetus Cells (in the blood)
13.6.7.1.3. Molecular
Diagnostics
13.6.7.1.4. Early
Stage Cancer
13.6.7.1.4.1. Lung
Cancer
13.6.7.1.4.2. Breast
Cancer
13.6.7.1.4.3. Colorectal
Cancer
13.6.7.1.4.4. Gastric
Cancer
13.6.7.1.4.5. Prostate
Cancer
13.6.7.1.4.6. Liver
Cancer
13.6.7.1.4.7. Bladder
Cancer
13.6.7.1.4.8. Ovarian
Cancer
13.6.7.1.4.9. Others
13.6.7.1.5. Non-invasive
Prenatal Tests (NIPT)
13.6.7.1.6. Others
13.6.7.2. Benelux
Union Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size
13.6.7.2.1. 5
ml
13.6.7.2.2. 50
ml
13.6.7.2.3. 100
ml
13.6.7.2.4. 250
ml
13.6.7.2.5. Above
250 ml
13.6.7.3. Benelux
Union Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering
13.6.7.3.1. Instruments
13.6.7.3.1.1. Blood
Collection Tube (BCT) for cfDNA and CTCs
13.6.7.3.1.2. Target
Selector Kits
13.6.7.3.1.3. Cell
Free DNA Extraction Kit
13.6.7.3.1.4. Cell
Free Nucleic Acid Extraction Kit
13.6.7.3.1.5. Mutation
Quantification Control Plasma
13.6.7.3.1.6. Genomic
Profiling Diagnostics kit
13.6.7.3.1.7. Target
Selector NGS Panels
13.6.7.3.1.8. PCR
Purification Kit
13.6.7.3.1.9. Blood
Nucleic Acid Extraction
13.6.7.3.1.10. Viral
Nucleic Acid Extraction
13.6.7.3.1.11. Others
13.6.7.3.2. Reagents
13.6.7.3.3. Liquid
Biopsy Assays
13.6.7.3.4. Tools
13.6.7.3.5. Services
13.6.7.3.5.1. Custom
Services
13.6.7.3.5.2. Support
Services
13.6.7.3.6. Others
13.6.7.4. Benelux
Union Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User
13.6.7.4.1. Hospitals/Clinics
13.6.7.4.2. Pathology
Laboratories
13.6.7.4.3. Physician
Laboratories
13.6.7.4.4. Academic
and Research Centers
13.6.7.4.5. Others
13.6.7.5. Benelux
Union Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Country
13.6.7.5.1. Belgium
13.6.7.5.2. The
Netherlands
13.6.7.5.3. Luxembourg
13.6.8. Rest of
Europe
13.6.8.1. Rest
of Europe Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By
Application
13.6.8.1.1. Circulating
Tumor Cells (CTC) in the Blood
13.6.8.1.2. Cell
Free DNA from Tumor or Fetus Cells (in the blood)
13.6.8.1.3. Molecular
Diagnostics
13.6.8.1.4. Early
Stage Cancer
13.6.8.1.4.1. Lung
Cancer
13.6.8.1.4.2. Breast
Cancer
13.6.8.1.4.3. Colorectal
Cancer
13.6.8.1.4.4. Gastric
Cancer
13.6.8.1.4.5. Prostate
Cancer
13.6.8.1.4.6. Liver
Cancer
13.6.8.1.4.7. Bladder
Cancer
13.6.8.1.4.8. Ovarian
Cancer
13.6.8.1.4.9. Others
13.6.8.1.5. Non-invasive
Prenatal Tests (NIPT)
13.6.8.1.6. Others
13.6.8.2. Rest
of Europe Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size
13.6.8.2.1. 5
ml
13.6.8.2.2. 50
ml
13.6.8.2.3. 100
ml
13.6.8.2.4. 250
ml
13.6.8.2.5. Above
250 ml
13.6.8.3. Rest
of Europe Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By
Offering
13.6.8.3.1. Instruments
13.6.8.3.1.1. Blood
Collection Tube (BCT) for cfDNA and CTCs
13.6.8.3.1.2. Target
Selector Kits
13.6.8.3.1.3. Cell
Free DNA Extraction Kit
13.6.8.3.1.4. Cell
Free Nucleic Acid Extraction Kit
13.6.8.3.1.5. Mutation
Quantification Control Plasma
13.6.8.3.1.6. Genomic
Profiling Diagnostics kit
13.6.8.3.1.7. Target
Selector NGS Panels
13.6.8.3.1.8. PCR
Purification Kit
13.6.8.3.1.9. Blood
Nucleic Acid Extraction
13.6.8.3.1.10. Viral
Nucleic Acid Extraction
13.6.8.3.1.11. Others
13.6.8.3.2. Reagents
13.6.8.3.3. Liquid
Biopsy Assays
13.6.8.3.4. Tools
13.6.8.3.5. Services
13.6.8.3.5.1. Custom
Services
13.6.8.3.5.2. Support
Services
13.6.8.3.6. Others
13.6.8.4. Rest of
Europe Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End
User
13.6.8.4.1. Hospitals/Clinics
13.6.8.4.2. Pathology
Laboratories
13.6.8.4.3. Physician
Laboratories
13.6.8.4.4. Academic
and Research Centers
13.6.8.4.5. Others
13.7. Key
Segment for Channeling Investments
13.7.1. By
Country
13.7.2. By
Application
13.7.3. By Size
13.7.4. By
Offering
13.7.5. By End
User
14. Asia
Pacific Liquid Biopsy Products Market Analysis and Forecasts, 2022 – 2030
14.1. Overview
14.1.1. Asia
Pacific Liquid Biopsy Products Market Revenue (US$ Mn)
14.2. Asia
Pacific Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application
14.2.1. Circulating
Tumor Cells (CTC) in the Blood
14.2.2. Cell
Free DNA from Tumor or Fetus Cells (in the blood)
14.2.3. Molecular
Diagnostics
14.2.4. Early
Stage Cancer
14.2.4.1. Lung
Cancer
14.2.4.2. Breast
Cancer
14.2.4.3. Colorectal
Cancer
14.2.4.4. Gastric
Cancer
14.2.4.5. Prostate
Cancer
14.2.4.6. Liver
Cancer
14.2.4.7. Bladder
Cancer
14.2.4.8. Ovarian
Cancer
14.2.4.9. Others
14.2.5. Non-invasive
Prenatal Tests (NIPT)
14.2.6. Others
14.3. Asia
Pacific Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size
14.3.1. 5 ml
14.3.2. 50 ml
14.3.3. 100 ml
14.3.4. 250 ml
14.3.5. Above
250 ml
14.4. Asia
Pacific Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By
Offering
14.4.1. Instruments
14.4.1.1. Blood
Collection Tube (BCT) for cfDNA and CTCs
14.4.1.2. Target
Selector Kits
14.4.1.3. Cell
Free DNA Extraction Kit
14.4.1.4. Cell
Free Nucleic Acid Extraction Kit
14.4.1.5. Mutation
Quantification Control Plasma
14.4.1.6. Genomic
Profiling Diagnostics kit
14.4.1.7. Target
Selector NGS Panels
14.4.1.8. PCR
Purification Kit
14.4.1.9. Blood
Nucleic Acid Extraction
14.4.1.10. Viral
Nucleic Acid Extraction
14.4.1.11. Others
14.4.2. Reagents
14.4.3. Liquid
Biopsy Assays
14.4.4. Tools
14.4.5. Services
14.4.5.1. Custom
Services
14.4.5.2. Support
Services
14.4.6. Others
14.5. Asia
Pacific Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End
User
14.5.1. Hospitals/Clinics
14.5.2. Pathology
Laboratories
14.5.3. Physician
Laboratories
14.5.4. Academic
and Research Centers
14.5.5. Others
14.6. Asia
Pacific Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By
Country
14.6.1. China
14.6.1.1. China
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application
14.6.1.1.1. Circulating
Tumor Cells (CTC) in the Blood
14.6.1.1.2. Cell
Free DNA from Tumor or Fetus Cells (in the blood)
14.6.1.1.3. Molecular
Diagnostics
14.6.1.1.4. Early
Stage Cancer
14.6.1.1.4.1. Lung
Cancer
14.6.1.1.4.2. Breast
Cancer
14.6.1.1.4.3. Colorectal
Cancer
14.6.1.1.4.4. Gastric
Cancer
14.6.1.1.4.5. Prostate
Cancer
14.6.1.1.4.6. Liver
Cancer
14.6.1.1.4.7. Bladder
Cancer
14.6.1.1.4.8. Ovarian
Cancer
14.6.1.1.4.9. Others
14.6.1.1.5. Non-invasive
Prenatal Tests (NIPT)
14.6.1.1.6. Others
14.6.1.2. China
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size
14.6.1.2.1. 5
ml
14.6.1.2.2. 50
ml
14.6.1.2.3. 100
ml
14.6.1.2.4. 250
ml
14.6.1.2.5. Above
250 ml
14.6.1.3. China
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering
14.6.1.3.1. Instruments
14.6.1.3.1.1. Blood
Collection Tube (BCT) for cfDNA and CTCs
14.6.1.3.1.2. Target
Selector Kits
14.6.1.3.1.3. Cell
Free DNA Extraction Kit
14.6.1.3.1.4. Cell
Free Nucleic Acid Extraction Kit
14.6.1.3.1.5. Mutation
Quantification Control Plasma
14.6.1.3.1.6. Genomic
Profiling Diagnostics kit
14.6.1.3.1.7. Target
Selector NGS Panels
14.6.1.3.1.8. PCR
Purification Kit
14.6.1.3.1.9. Blood
Nucleic Acid Extraction
14.6.1.3.1.10. Viral
Nucleic Acid Extraction
14.6.1.3.1.11. Others
14.6.1.3.2. Reagents
14.6.1.3.3. Liquid
Biopsy Assays
14.6.1.3.4. Tools
14.6.1.3.5. Services
14.6.1.3.5.1. Custom
Services
14.6.1.3.5.2. Support
Services
14.6.1.3.6. Others
14.6.1.4. China
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User
14.6.1.4.1. Hospitals/Clinics
14.6.1.4.2. Pathology
Laboratories
14.6.1.4.3. Physician
Laboratories
14.6.1.4.4. Academic
and Research Centers
14.6.1.4.5. Others
14.6.2. Japan
14.6.2.1. Japan
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application
14.6.2.1.1. Circulating
Tumor Cells (CTC) in the Blood
14.6.2.1.2. Cell
Free DNA from Tumor or Fetus Cells (in the blood)
14.6.2.1.3. Molecular
Diagnostics
14.6.2.1.4. Early
Stage Cancer
14.6.2.1.4.1. Lung
Cancer
14.6.2.1.4.2. Breast
Cancer
14.6.2.1.4.3. Colorectal
Cancer
14.6.2.1.4.4. Gastric
Cancer
14.6.2.1.4.5. Prostate
Cancer
14.6.2.1.4.6. Liver
Cancer
14.6.2.1.4.7. Bladder
Cancer
14.6.2.1.4.8. Ovarian
Cancer
14.6.2.1.4.9. Others
14.6.2.1.5. Non-invasive
Prenatal Tests (NIPT)
14.6.2.1.6. Others
14.6.2.2. Japan
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size
14.6.2.2.1. 5
ml
14.6.2.2.2. 50
ml
14.6.2.2.3. 100
ml
14.6.2.2.4. 250
ml
14.6.2.2.5. Above
250 ml
14.6.2.3. Japan
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering
14.6.2.3.1. Instruments
14.6.2.3.1.1. Blood
Collection Tube (BCT) for cfDNA and CTCs
14.6.2.3.1.2. Target
Selector Kits
14.6.2.3.1.3. Cell
Free DNA Extraction Kit
14.6.2.3.1.4. Cell
Free Nucleic Acid Extraction Kit
14.6.2.3.1.5. Mutation
Quantification Control Plasma
14.6.2.3.1.6. Genomic
Profiling Diagnostics kit
14.6.2.3.1.7. Target
Selector NGS Panels
14.6.2.3.1.8. PCR
Purification Kit
14.6.2.3.1.9. Blood
Nucleic Acid Extraction
14.6.2.3.1.10. Viral
Nucleic Acid Extraction
14.6.2.3.1.11. Others
14.6.2.3.2. Reagents
14.6.2.3.3. Liquid
Biopsy Assays
14.6.2.3.4. Tools
14.6.2.3.5. Services
14.6.2.3.5.1. Custom
Services
14.6.2.3.5.2. Support
Services
14.6.2.3.6. Others
14.6.2.4. Japan
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User
14.6.2.4.1. Hospitals/Clinics
14.6.2.4.2. Pathology
Laboratories
14.6.2.4.3. Physician
Laboratories
14.6.2.4.4. Academic
and Research Centers
14.6.2.4.5. Others
14.6.3. India
14.6.3.1. India
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application
14.6.3.1.1. Circulating
Tumor Cells (CTC) in the Blood
14.6.3.1.2. Cell
Free DNA from Tumor or Fetus Cells (in the blood)
14.6.3.1.3. Molecular
Diagnostics
14.6.3.1.4. Early
Stage Cancer
14.6.3.1.4.1. Lung
Cancer
14.6.3.1.4.2. Breast
Cancer
14.6.3.1.4.3. Colorectal
Cancer
14.6.3.1.4.4. Gastric
Cancer
14.6.3.1.4.5. Prostate
Cancer
14.6.3.1.4.6. Liver
Cancer
14.6.3.1.4.7. Bladder
Cancer
14.6.3.1.4.8. Ovarian
Cancer
14.6.3.1.4.9. Others
14.6.3.1.5. Non-invasive
Prenatal Tests (NIPT)
14.6.3.1.6. Others
14.6.3.2. India
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size
14.6.3.2.1. 5
ml
14.6.3.2.2. 50
ml
14.6.3.2.3. 100
ml
14.6.3.2.4. 250
ml
14.6.3.2.5. Above
250 ml
14.6.3.3. India
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering
14.6.3.3.1. Instruments
14.6.3.3.1.1. Blood
Collection Tube (BCT) for cfDNA and CTCs
14.6.3.3.1.2. Target
Selector Kits
14.6.3.3.1.3. Cell
Free DNA Extraction Kit
14.6.3.3.1.4. Cell
Free Nucleic Acid Extraction Kit
14.6.3.3.1.5. Mutation
Quantification Control Plasma
14.6.3.3.1.6. Genomic
Profiling Diagnostics kit
14.6.3.3.1.7. Target
Selector NGS Panels
14.6.3.3.1.8. PCR
Purification Kit
14.6.3.3.1.9. Blood
Nucleic Acid Extraction
14.6.3.3.1.10. Viral
Nucleic Acid Extraction
14.6.3.3.1.11. Others
14.6.3.3.2. Reagents
14.6.3.3.3. Liquid
Biopsy Assays
14.6.3.3.4. Tools
14.6.3.3.5. Services
14.6.3.3.5.1. Custom
Services
14.6.3.3.5.2. Support
Services
14.6.3.3.6. Others
14.6.3.4. India
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User
14.6.3.4.1. Hospitals/Clinics
14.6.3.4.2. Pathology
Laboratories
14.6.3.4.3. Physician
Laboratories
14.6.3.4.4. Academic
and Research Centers
14.6.3.4.5. Others
14.6.4. New
Zealand
14.6.4.1. New
Zealand Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By
Application
14.6.4.1.1. Circulating
Tumor Cells (CTC) in the Blood
14.6.4.1.2. Cell
Free DNA from Tumor or Fetus Cells (in the blood)
14.6.4.1.3. Molecular
Diagnostics
14.6.4.1.4. Early
Stage Cancer
14.6.4.1.4.1. Lung
Cancer
14.6.4.1.4.2. Breast
Cancer
14.6.4.1.4.3. Colorectal
Cancer
14.6.4.1.4.4. Gastric
Cancer
14.6.4.1.4.5. Prostate
Cancer
14.6.4.1.4.6. Liver
Cancer
14.6.4.1.4.7. Bladder
Cancer
14.6.4.1.4.8. Ovarian
Cancer
14.6.4.1.4.9. Others
14.6.4.1.5. Non-invasive
Prenatal Tests (NIPT)
14.6.4.1.6. Others
14.6.4.2. New
Zealand Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size
14.6.4.2.1. 5
ml
14.6.4.2.2. 50
ml
14.6.4.2.3. 100
ml
14.6.4.2.4. 250
ml
14.6.4.2.5. Above
250 ml
14.6.4.3. New
Zealand Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By
Offering
14.6.4.3.1. Instruments
14.6.4.3.1.1. Blood
Collection Tube (BCT) for cfDNA and CTCs
14.6.4.3.1.2. Target
Selector Kits
14.6.4.3.1.3. Cell
Free DNA Extraction Kit
14.6.4.3.1.4. Cell
Free Nucleic Acid Extraction Kit
14.6.4.3.1.5. Mutation
Quantification Control Plasma
14.6.4.3.1.6. Genomic
Profiling Diagnostics kit
14.6.4.3.1.7. Target
Selector NGS Panels
14.6.4.3.1.8. PCR
Purification Kit
14.6.4.3.1.9. Blood
Nucleic Acid Extraction
14.6.4.3.1.10. Viral
Nucleic Acid Extraction
14.6.4.3.1.11. Others
14.6.4.3.2. Reagents
14.6.4.3.3. Liquid
Biopsy Assays
14.6.4.3.4. Tools
14.6.4.3.5. Services
14.6.4.3.5.1. Custom
Services
14.6.4.3.5.2. Support
Services
14.6.4.3.6. Others
14.6.4.4. New
Zealand Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End
User
14.6.4.4.1. Hospitals/Clinics
14.6.4.4.2. Pathology
Laboratories
14.6.4.4.3. Physician
Laboratories
14.6.4.4.4. Academic
and Research Centers
14.6.4.4.5. Others
14.6.5. Australia
14.6.5.1. Australia
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application
14.6.5.1.1. Circulating
Tumor Cells (CTC) in the Blood
14.6.5.1.2. Cell
Free DNA from Tumor or Fetus Cells (in the blood)
14.6.5.1.3. Molecular
Diagnostics
14.6.5.1.4. Early
Stage Cancer
14.6.5.1.4.1. Lung
Cancer
14.6.5.1.4.2. Breast
Cancer
14.6.5.1.4.3. Colorectal
Cancer
14.6.5.1.4.4. Gastric
Cancer
14.6.5.1.4.5. Prostate
Cancer
14.6.5.1.4.6. Liver
Cancer
14.6.5.1.4.7. Bladder
Cancer
14.6.5.1.4.8. Ovarian
Cancer
14.6.5.1.4.9. Others
14.6.5.1.5. Non-invasive
Prenatal Tests (NIPT)
14.6.5.1.6. Others
14.6.5.2. Australia
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size
14.6.5.2.1. 5
ml
14.6.5.2.2. 50
ml
14.6.5.2.3. 100
ml
14.6.5.2.4. 250
ml
14.6.5.2.5. Above
250 ml
14.6.5.3. Australia
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering
14.6.5.3.1. Instruments
14.6.5.3.1.1. Blood
Collection Tube (BCT) for cfDNA and CTCs
14.6.5.3.1.2. Target
Selector Kits
14.6.5.3.1.3. Cell
Free DNA Extraction Kit
14.6.5.3.1.4. Cell
Free Nucleic Acid Extraction Kit
14.6.5.3.1.5. Mutation
Quantification Control Plasma
14.6.5.3.1.6. Genomic
Profiling Diagnostics kit
14.6.5.3.1.7. Target
Selector NGS Panels
14.6.5.3.1.8. PCR
Purification Kit
14.6.5.3.1.9. Blood
Nucleic Acid Extraction
14.6.5.3.1.10. Viral
Nucleic Acid Extraction
14.6.5.3.1.11. Others
14.6.5.3.2. Reagents
14.6.5.3.3. Liquid
Biopsy Assays
14.6.5.3.4. Tools
14.6.5.3.5. Services
14.6.5.3.5.1. Custom
Services
14.6.5.3.5.2. Support
Services
14.6.5.3.6. Others
14.6.5.4. Australia
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User
14.6.5.4.1. Hospitals/Clinics
14.6.5.4.2. Pathology
Laboratories
14.6.5.4.3. Physician
Laboratories
14.6.5.4.4. Academic
and Research Centers
14.6.5.4.5. Others
14.6.6. South
Korea
14.6.6.1. South
Korea Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By
Application
14.6.6.1.1. Circulating
Tumor Cells (CTC) in the Blood
14.6.6.1.2. Cell
Free DNA from Tumor or Fetus Cells (in the blood)
14.6.6.1.3. Molecular
Diagnostics
14.6.6.1.4. Early
Stage Cancer
14.6.6.1.4.1. Lung
Cancer
14.6.6.1.4.2. Breast
Cancer
14.6.6.1.4.3. Colorectal
Cancer
14.6.6.1.4.4. Gastric
Cancer
14.6.6.1.4.5. Prostate
Cancer
14.6.6.1.4.6. Liver
Cancer
14.6.6.1.4.7. Bladder
Cancer
14.6.6.1.4.8. Ovarian
Cancer
14.6.6.1.4.9. Others
14.6.6.1.5. Non-invasive
Prenatal Tests (NIPT)
14.6.6.1.6. Others
14.6.6.2. South
Korea Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size
14.6.6.2.1. 5
ml
14.6.6.2.2. 50
ml
14.6.6.2.3. 100
ml
14.6.6.2.4. 250
ml
14.6.6.2.5. Above
250 ml
14.6.6.3. South
Korea Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering
14.6.6.3.1. Instruments
14.6.6.3.1.1. Blood
Collection Tube (BCT) for cfDNA and CTCs
14.6.6.3.1.2. Target
Selector Kits
14.6.6.3.1.3. Cell
Free DNA Extraction Kit
14.6.6.3.1.4. Cell
Free Nucleic Acid Extraction Kit
14.6.6.3.1.5. Mutation
Quantification Control Plasma
14.6.6.3.1.6. Genomic
Profiling Diagnostics kit
14.6.6.3.1.7. Target
Selector NGS Panels
14.6.6.3.1.8. PCR
Purification Kit
14.6.6.3.1.9. Blood
Nucleic Acid Extraction
14.6.6.3.1.10. Viral
Nucleic Acid Extraction
14.6.6.3.1.11. Others
14.6.6.3.2. Reagents
14.6.6.3.3. Liquid
Biopsy Assays
14.6.6.3.4. Tools
14.6.6.3.5. Services
14.6.6.3.5.1. Custom
Services
14.6.6.3.5.2. Support
Services
14.6.6.3.6. Others
14.6.6.4. South
Korea Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User
14.6.6.4.1. Hospitals/Clinics
14.6.6.4.2. Pathology
Laboratories
14.6.6.4.3. Physician
Laboratories
14.6.6.4.4. Academic
and Research Centers
14.6.6.4.5. Others
14.6.7. Southeast
Asia
14.6.7.1. Southeast
Asia Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By
Application
14.6.7.1.1. Circulating
Tumor Cells (CTC) in the Blood
14.6.7.1.2. Cell
Free DNA from Tumor or Fetus Cells (in the blood)
14.6.7.1.3. Molecular
Diagnostics
14.6.7.1.4. Early
Stage Cancer
14.6.7.1.4.1. Lung
Cancer
14.6.7.1.4.2. Breast
Cancer
14.6.7.1.4.3. Colorectal
Cancer
14.6.7.1.4.4. Gastric
Cancer
14.6.7.1.4.5. Prostate
Cancer
14.6.7.1.4.6. Liver
Cancer
14.6.7.1.4.7. Bladder
Cancer
14.6.7.1.4.8. Ovarian
Cancer
14.6.7.1.4.9. Others
14.6.7.1.5. Non-invasive
Prenatal Tests (NIPT)
14.6.7.1.6. Others
14.6.7.2. Southeast
Asia Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size
14.6.7.2.1. 5
ml
14.6.7.2.2. 50
ml
14.6.7.2.3. 100
ml
14.6.7.2.4. 250
ml
14.6.7.2.5. Above
250 ml
14.6.7.3. Southeast
Asia Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering
14.6.7.3.1. Instruments
14.6.7.3.1.1. Blood
Collection Tube (BCT) for cfDNA and CTCs
14.6.7.3.1.2. Target
Selector Kits
14.6.7.3.1.3. Cell
Free DNA Extraction Kit
14.6.7.3.1.4. Cell
Free Nucleic Acid Extraction Kit
14.6.7.3.1.5. Mutation
Quantification Control Plasma
14.6.7.3.1.6. Genomic
Profiling Diagnostics kit
14.6.7.3.1.7. Target
Selector NGS Panels
14.6.7.3.1.8. PCR
Purification Kit
14.6.7.3.1.9. Blood
Nucleic Acid Extraction
14.6.7.3.1.10. Viral
Nucleic Acid Extraction
14.6.7.3.1.11. Others
14.6.7.3.2. Reagents
14.6.7.3.3. Liquid
Biopsy Assays
14.6.7.3.4. Tools
14.6.7.3.5. Services
14.6.7.3.5.1. Custom
Services
14.6.7.3.5.2. Support
Services
14.6.7.3.6. Others
14.6.7.4. Southeast
Asia Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User
14.6.7.4.1. Hospitals/Clinics
14.6.7.4.2. Pathology
Laboratories
14.6.7.4.3. Physician
Laboratories
14.6.7.4.4. Academic
and Research Centers
14.6.7.4.5. Others
14.6.7.5. Southeast
Asia Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Country
14.6.7.5.1. Indonesia
14.6.7.5.2. Thailand
14.6.7.5.3. Malaysia
14.6.7.5.4. Singapore
14.6.7.5.5. Rest
of Southeast Asia
14.6.8. Rest of
Asia Pacific
14.6.8.1. Rest
of Asia Pacific Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts,
By Application
14.6.8.1.1. Circulating
Tumor Cells (CTC) in the Blood
14.6.8.1.2. Cell
Free DNA from Tumor or Fetus Cells (in the blood)
14.6.8.1.3. Molecular
Diagnostics
14.6.8.1.4. Early
Stage Cancer
14.6.8.1.4.1. Lung
Cancer
14.6.8.1.4.2. Breast
Cancer
14.6.8.1.4.3. Colorectal
Cancer
14.6.8.1.4.4. Gastric
Cancer
14.6.8.1.4.5. Prostate
Cancer
14.6.8.1.4.6. Liver
Cancer
14.6.8.1.4.7. Bladder
Cancer
14.6.8.1.4.8. Ovarian
Cancer
14.6.8.1.4.9. Others
14.6.8.1.5. Non-invasive
Prenatal Tests (NIPT)
14.6.8.1.6. Others
14.6.8.2. Rest
of Asia Pacific Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts,
By Size
14.6.8.2.1. 5
ml
14.6.8.2.2. 50
ml
14.6.8.2.3. 100
ml
14.6.8.2.4. 250
ml
14.6.8.2.5. Above
250 ml
14.6.8.3. Rest
of Asia Pacific Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts,
By Offering
14.6.8.3.1. Instruments
14.6.8.3.1.1. Blood
Collection Tube (BCT) for cfDNA and CTCs
14.6.8.3.1.2. Target
Selector Kits
14.6.8.3.1.3. Cell
Free DNA Extraction Kit
14.6.8.3.1.4. Cell
Free Nucleic Acid Extraction Kit
14.6.8.3.1.5. Mutation
Quantification Control Plasma
14.6.8.3.1.6. Genomic
Profiling Diagnostics kit
14.6.8.3.1.7. Target
Selector NGS Panels
14.6.8.3.1.8. PCR
Purification Kit
14.6.8.3.1.9. Blood
Nucleic Acid Extraction
14.6.8.3.1.10. Viral
Nucleic Acid Extraction
14.6.8.3.1.11. Others
14.6.8.3.2. Reagents
14.6.8.3.3. Liquid
Biopsy Assays
14.6.8.3.4. Tools
14.6.8.3.5. Services
14.6.8.3.5.1. Custom
Services
14.6.8.3.5.2. Support
Services
14.6.8.3.6. Others
14.6.8.4. Rest
of Asia Pacific Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts,
By End User
14.6.8.4.1. Hospitals/Clinics
14.6.8.4.2. Pathology
Laboratories
14.6.8.4.3. Physician
Laboratories
14.6.8.4.4. Academic
and Research Centers
14.6.8.4.5. Others
14.7. Key
Segment for Channeling Investments
14.7.1. By
Country
14.7.2. By
Application
14.7.3. By Size
14.7.4. By
Offering
14.7.5. By End User
15. Middle
East and Africa Liquid Biopsy Products Market Analysis and Forecasts, 2022 –
2030
15.1. Overview
15.1.1. Middle
East and Africa Liquid Biopsy Products Market Revenue (US$ Mn)
15.2. Middle
East and Africa Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts,
By Application
15.2.1. Circulating
Tumor Cells (CTC) in the Blood
15.2.2. Cell
Free DNA from Tumor or Fetus Cells (in the blood)
15.2.3. Molecular
Diagnostics
15.2.4. Early
Stage Cancer
15.2.4.1. Lung
Cancer
15.2.4.2. Breast
Cancer
15.2.4.3. Colorectal
Cancer
15.2.4.4. Gastric
Cancer
15.2.4.5. Prostate
Cancer
15.2.4.6. Liver
Cancer
15.2.4.7. Bladder
Cancer
15.2.4.8. Ovarian
Cancer
15.2.4.9. Others
15.2.5. Non-invasive
Prenatal Tests (NIPT)
15.2.6. Others
15.3. Middle
East and Africa Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts,
By Size
15.3.1. 5 ml
15.3.2. 50 ml
15.3.3. 100 ml
15.3.4. 250 ml
15.3.5. Above
250 ml
15.4. Middle
East and Africa Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts,
By Offering
15.4.1. Instruments
15.4.1.1. Blood
Collection Tube (BCT) for cfDNA and CTCs
15.4.1.2. Target
Selector Kits
15.4.1.3. Cell
Free DNA Extraction Kit
15.4.1.4. Cell
Free Nucleic Acid Extraction Kit
15.4.1.5. Mutation
Quantification Control Plasma
15.4.1.6. Genomic
Profiling Diagnostics kit
15.4.1.7. Target
Selector NGS Panels
15.4.1.8. PCR
Purification Kit
15.4.1.9. Blood
Nucleic Acid Extraction
15.4.1.10. Viral
Nucleic Acid Extraction
15.4.1.11. Others
15.4.2. Reagents
15.4.3. Liquid
Biopsy Assays
15.4.4. Tools
15.4.5. Services
15.4.5.1. Custom
Services
15.4.5.2. Support
Services
15.4.6. Others
15.5. Middle
East and Africa Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts,
By End User
15.5.1. Hospitals/Clinics
15.5.2. Pathology
Laboratories
15.5.3. Physician
Laboratories
15.5.4. Academic
and Research Centers
15.5.5. Others
15.6. Middle
East and Africa Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts,
By Country
15.6.1. Saudi
Arabia
15.6.1.1. Saudi
Arabia Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By
Application
15.6.1.1.1. Circulating
Tumor Cells (CTC) in the Blood
15.6.1.1.2. Cell
Free DNA from Tumor or Fetus Cells (in the blood)
15.6.1.1.3. Molecular
Diagnostics
15.6.1.1.4. Early
Stage Cancer
15.6.1.1.4.1. Lung
Cancer
15.6.1.1.4.2. Breast
Cancer
15.6.1.1.4.3. Colorectal
Cancer
15.6.1.1.4.4. Gastric
Cancer
15.6.1.1.4.5. Prostate
Cancer
15.6.1.1.4.6. Liver
Cancer
15.6.1.1.4.7. Bladder
Cancer
15.6.1.1.4.8. Ovarian
Cancer
15.6.1.1.4.9. Others
15.6.1.1.5. Non-invasive
Prenatal Tests (NIPT)
15.6.1.1.6. Others
15.6.1.2. Saudi
Arabia Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size
15.6.1.2.1. 5
ml
15.6.1.2.2. 50
ml
15.6.1.2.3. 100
ml
15.6.1.2.4. 250
ml
15.6.1.2.5. Above
250 ml
15.6.1.3. Saudi
Arabia Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By
Offering
15.6.1.3.1. Instruments
15.6.1.3.1.1. Blood
Collection Tube (BCT) for cfDNA and CTCs
15.6.1.3.1.2. Target
Selector Kits
15.6.1.3.1.3. Cell
Free DNA Extraction Kit
15.6.1.3.1.4. Cell
Free Nucleic Acid Extraction Kit
15.6.1.3.1.5. Mutation
Quantification Control Plasma
15.6.1.3.1.6. Genomic
Profiling Diagnostics kit
15.6.1.3.1.7. Target
Selector NGS Panels
15.6.1.3.1.8. PCR
Purification Kit
15.6.1.3.1.9. Blood
Nucleic Acid Extraction
15.6.1.3.1.10. Viral
Nucleic Acid Extraction
15.6.1.3.1.11. Others
15.6.1.3.2. Reagents
15.6.1.3.3. Liquid
Biopsy Assays
15.6.1.3.4. Tools
15.6.1.3.5. Services
15.6.1.3.5.1. Custom
Services
15.6.1.3.5.2. Support
Services
15.6.1.3.6. Others
15.6.1.4. Saudi
Arabia Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End
User
15.6.1.4.1. Hospitals/Clinics
15.6.1.4.2. Pathology
Laboratories
15.6.1.4.3. Physician
Laboratories
15.6.1.4.4. Academic
and Research Centers
15.6.1.4.5. Others
15.6.2. UAE
15.6.2.1. UAE
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application
15.6.2.1.1. Circulating
Tumor Cells (CTC) in the Blood
15.6.2.1.2. Cell
Free DNA from Tumor or Fetus Cells (in the blood)
15.6.2.1.3. Molecular
Diagnostics
15.6.2.1.4. Early
Stage Cancer
15.6.2.1.4.1. Lung
Cancer
15.6.2.1.4.2. Breast
Cancer
15.6.2.1.4.3. Colorectal
Cancer
15.6.2.1.4.4. Gastric
Cancer
15.6.2.1.4.5. Prostate
Cancer
15.6.2.1.4.6. Liver
Cancer
15.6.2.1.4.7. Bladder
Cancer
15.6.2.1.4.8. Ovarian
Cancer
15.6.2.1.4.9. Others
15.6.2.1.5. Non-invasive
Prenatal Tests (NIPT)
15.6.2.1.6. Others
15.6.2.2. UAE
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size
15.6.2.2.1. 5
ml
15.6.2.2.2. 50
ml
15.6.2.2.3. 100
ml
15.6.2.2.4. 250
ml
15.6.2.2.5. Above
250 ml
15.6.2.3. UAE
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering
15.6.2.3.1. Instruments
15.6.2.3.1.1. Blood
Collection Tube (BCT) for cfDNA and CTCs
15.6.2.3.1.2. Target
Selector Kits
15.6.2.3.1.3. Cell
Free DNA Extraction Kit
15.6.2.3.1.4. Cell
Free Nucleic Acid Extraction Kit
15.6.2.3.1.5. Mutation
Quantification Control Plasma
15.6.2.3.1.6. Genomic
Profiling Diagnostics kit
15.6.2.3.1.7. Target
Selector NGS Panels
15.6.2.3.1.8. PCR
Purification Kit
15.6.2.3.1.9. Blood
Nucleic Acid Extraction
15.6.2.3.1.10. Viral
Nucleic Acid Extraction
15.6.2.3.1.11. Others
15.6.2.3.2. Reagents
15.6.2.3.3. Liquid
Biopsy Assays
15.6.2.3.4. Tools
15.6.2.3.5. Services
15.6.2.3.5.1. Custom
Services
15.6.2.3.5.2. Support
Services
15.6.2.3.6. Others
15.6.2.4. UAE
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User
15.6.2.4.1. Hospitals/Clinics
15.6.2.4.2. Pathology
Laboratories
15.6.2.4.3. Physician
Laboratories
15.6.2.4.4. Academic
and Research Centers
15.6.2.4.5. Others
15.6.3. Egypt
15.6.3.1. Egypt
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application
15.6.3.1.1. Circulating
Tumor Cells (CTC) in the Blood
15.6.3.1.2. Cell
Free DNA from Tumor or Fetus Cells (in the blood)
15.6.3.1.3. Molecular
Diagnostics
15.6.3.1.4. Early
Stage Cancer
15.6.3.1.4.1. Lung
Cancer
15.6.3.1.4.2. Breast
Cancer
15.6.3.1.4.3. Colorectal
Cancer
15.6.3.1.4.4. Gastric
Cancer
15.6.3.1.4.5. Prostate
Cancer
15.6.3.1.4.6. Liver
Cancer
15.6.3.1.4.7. Bladder
Cancer
15.6.3.1.4.8. Ovarian
Cancer
15.6.3.1.4.9. Others
15.6.3.1.5. Non-invasive
Prenatal Tests (NIPT)
15.6.3.1.6. Others
15.6.3.2. Egypt
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size
15.6.3.2.1. 5
ml
15.6.3.2.2. 50
ml
15.6.3.2.3. 100
ml
15.6.3.2.4. 250
ml
15.6.3.2.5. Above
250 ml
15.6.3.3. Egypt
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering
15.6.3.3.1. Instruments
15.6.3.3.1.1. Blood
Collection Tube (BCT) for cfDNA and CTCs
15.6.3.3.1.2. Target
Selector Kits
15.6.3.3.1.3. Cell
Free DNA Extraction Kit
15.6.3.3.1.4. Cell
Free Nucleic Acid Extraction Kit
15.6.3.3.1.5. Mutation
Quantification Control Plasma
15.6.3.3.1.6. Genomic
Profiling Diagnostics kit
15.6.3.3.1.7. Target
Selector NGS Panels
15.6.3.3.1.8. PCR
Purification Kit
15.6.3.3.1.9. Blood
Nucleic Acid Extraction
15.6.3.3.1.10. Viral
Nucleic Acid Extraction
15.6.3.3.1.11. Others
15.6.3.3.2. Reagents
15.6.3.3.3. Liquid
Biopsy Assays
15.6.3.3.4. Tools
15.6.3.3.5. Services
15.6.3.3.5.1. Custom
Services
15.6.3.3.5.2. Support
Services
15.6.3.3.6. Others
15.6.3.4. Egypt
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User
15.6.3.4.1. Hospitals/Clinics
15.6.3.4.2. Pathology
Laboratories
15.6.3.4.3. Physician
Laboratories
15.6.3.4.4. Academic
and Research Centers
15.6.3.4.5. Others
15.6.4. Kuwait
15.6.4.1. Kuwait
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application
15.6.4.1.1. Circulating
Tumor Cells (CTC) in the Blood
15.6.4.1.2. Cell
Free DNA from Tumor or Fetus Cells (in the blood)
15.6.4.1.3. Molecular
Diagnostics
15.6.4.1.4. Early
Stage Cancer
15.6.4.1.4.1. Lung
Cancer
15.6.4.1.4.2. Breast
Cancer
15.6.4.1.4.3. Colorectal
Cancer
15.6.4.1.4.4. Gastric
Cancer
15.6.4.1.4.5. Prostate
Cancer
15.6.4.1.4.6. Liver
Cancer
15.6.4.1.4.7. Bladder
Cancer
15.6.4.1.4.8. Ovarian
Cancer
15.6.4.1.4.9. Others
15.6.4.1.5. Non-invasive
Prenatal Tests (NIPT)
15.6.4.1.6. Others
15.6.4.2. Kuwait
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size
15.6.4.2.1. 5
ml
15.6.4.2.2. 50
ml
15.6.4.2.3. 100
ml
15.6.4.2.4. 250
ml
15.6.4.2.5. Above
250 ml
15.6.4.3. Kuwait
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering
15.6.4.3.1. Instruments
15.6.4.3.1.1. Blood
Collection Tube (BCT) for cfDNA and CTCs
15.6.4.3.1.2. Target
Selector Kits
15.6.4.3.1.3. Cell
Free DNA Extraction Kit
15.6.4.3.1.4. Cell
Free Nucleic Acid Extraction Kit
15.6.4.3.1.5. Mutation
Quantification Control Plasma
15.6.4.3.1.6. Genomic
Profiling Diagnostics kit
15.6.4.3.1.7. Target
Selector NGS Panels
15.6.4.3.1.8. PCR
Purification Kit
15.6.4.3.1.9. Blood
Nucleic Acid Extraction
15.6.4.3.1.10. Viral
Nucleic Acid Extraction
15.6.4.3.1.11. Others
15.6.4.3.2. Reagents
15.6.4.3.3. Liquid
Biopsy Assays
15.6.4.3.4. Tools
15.6.4.3.5. Services
15.6.4.3.5.1. Custom
Services
15.6.4.3.5.2. Support
Services
15.6.4.3.6. Others
15.6.4.4. Kuwait
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User
15.6.4.4.1. Hospitals/Clinics
15.6.4.4.2. Pathology
Laboratories
15.6.4.4.3. Physician
Laboratories
15.6.4.4.4. Academic
and Research Centers
15.6.4.4.5. Others
15.6.5. South
Africa
15.6.5.1. South
Africa Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By
Application
15.6.5.1.1. Circulating
Tumor Cells (CTC) in the Blood
15.6.5.1.2. Cell
Free DNA from Tumor or Fetus Cells (in the blood)
15.6.5.1.3. Molecular
Diagnostics
15.6.5.1.4. Early
Stage Cancer
15.6.5.1.4.1. Lung
Cancer
15.6.5.1.4.2. Breast
Cancer
15.6.5.1.4.3. Colorectal
Cancer
15.6.5.1.4.4. Gastric
Cancer
15.6.5.1.4.5. Prostate
Cancer
15.6.5.1.4.6. Liver
Cancer
15.6.5.1.4.7. Bladder
Cancer
15.6.5.1.4.8. Ovarian
Cancer
15.6.5.1.4.9. Others
15.6.5.1.5. Non-invasive
Prenatal Tests (NIPT)
15.6.5.1.6. Others
15.6.5.2. South
Africa Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size
15.6.5.2.1. 5
ml
15.6.5.2.2. 50
ml
15.6.5.2.3. 100
ml
15.6.5.2.4. 250
ml
15.6.5.2.5. Above
250 ml
15.6.5.3. South
Africa Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By
Offering
15.6.5.3.1. Instruments
15.6.5.3.1.1. Blood
Collection Tube (BCT) for cfDNA and CTCs
15.6.5.3.1.2. Target
Selector Kits
15.6.5.3.1.3. Cell
Free DNA Extraction Kit
15.6.5.3.1.4. Cell
Free Nucleic Acid Extraction Kit
15.6.5.3.1.5. Mutation
Quantification Control Plasma
15.6.5.3.1.6. Genomic
Profiling Diagnostics kit
15.6.5.3.1.7. Target
Selector NGS Panels
15.6.5.3.1.8. PCR
Purification Kit
15.6.5.3.1.9. Blood
Nucleic Acid Extraction
15.6.5.3.1.10. Viral
Nucleic Acid Extraction
15.6.5.3.1.11. Others
15.6.5.3.2. Reagents
15.6.5.3.3. Liquid
Biopsy Assays
15.6.5.3.4. Tools
15.6.5.3.5. Services
15.6.5.3.5.1. Custom
Services
15.6.5.3.5.2. Support
Services
15.6.5.3.6. Others
15.6.5.4. South
Africa Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End
User
15.6.5.4.1. Hospitals/Clinics
15.6.5.4.2. Pathology
Laboratories
15.6.5.4.3. Physician
Laboratories
15.6.5.4.4. Academic
and Research Centers
15.6.5.4.5. Others
15.6.6. Rest of
Middle East & Africa
15.6.6.1. Rest
of Middle East & Africa Liquid Biopsy Products Market Revenue (US$ Mn) and
Forecasts, By Application
15.6.6.1.1. Circulating
Tumor Cells (CTC) in the Blood
15.6.6.1.2. Cell
Free DNA from Tumor or Fetus Cells (in the blood)
15.6.6.1.3. Molecular
Diagnostics
15.6.6.1.4. Early
Stage Cancer
15.6.6.1.4.1. Lung
Cancer
15.6.6.1.4.2. Breast
Cancer
15.6.6.1.4.3. Colorectal
Cancer
15.6.6.1.4.4. Gastric
Cancer
15.6.6.1.4.5. Prostate
Cancer
15.6.6.1.4.6. Liver
Cancer
15.6.6.1.4.7. Bladder
Cancer
15.6.6.1.4.8. Ovarian
Cancer
15.6.6.1.4.9. Others
15.6.6.1.5. Non-invasive
Prenatal Tests (NIPT)
15.6.6.1.6. Others
15.6.6.2. Rest
of Middle East & Africa Liquid Biopsy Products Market Revenue (US$ Mn) and
Forecasts, By Size
15.6.6.2.1. 5
ml
15.6.6.2.2. 50
ml
15.6.6.2.3. 100
ml
15.6.6.2.4. 250
ml
15.6.6.2.5. Above
250 ml
15.6.6.3. Rest
of Middle East & Africa Liquid Biopsy Products Market Revenue (US$ Mn) and
Forecasts, By Offering
15.6.6.3.1. Instruments
15.6.6.3.1.1. Blood
Collection Tube (BCT) for cfDNA and CTCs
15.6.6.3.1.2. Target
Selector Kits
15.6.6.3.1.3. Cell
Free DNA Extraction Kit
15.6.6.3.1.4. Cell
Free Nucleic Acid Extraction Kit
15.6.6.3.1.5. Mutation
Quantification Control Plasma
15.6.6.3.1.6. Genomic
Profiling Diagnostics kit
15.6.6.3.1.7. Target
Selector NGS Panels
15.6.6.3.1.8. PCR
Purification Kit
15.6.6.3.1.9. Blood
Nucleic Acid Extraction
15.6.6.3.1.10. Viral
Nucleic Acid Extraction
15.6.6.3.1.11. Others
15.6.6.3.2. Reagents
15.6.6.3.3. Liquid
Biopsy Assays
15.6.6.3.4. Tools
15.6.6.3.5. Services
15.6.6.3.5.1. Custom
Services
15.6.6.3.5.2. Support
Services
15.6.6.3.6. Others
15.6.6.4. Rest
of Middle East & Africa Liquid Biopsy Products Market Revenue (US$ Mn) and
Forecasts, By End User
15.6.6.4.1. Hospitals/Clinics
15.6.6.4.2. Pathology
Laboratories
15.6.6.4.3. Physician
Laboratories
15.6.6.4.4. Academic
and Research Centers
15.6.6.4.5. Others
15.7. Key
Segment for Channeling Investments
15.7.1. By
Country
15.7.2. By
Application
15.7.3. By Size
15.7.4. By
Offering
15.7.5. By End
User
16. Latin
America Liquid Biopsy Products Market Analysis and Forecasts, 2022 – 2030
16.1. Overview
16.1.1. Latin
America Liquid Biopsy Products Market Revenue (US$ Mn)
16.2. Latin
America Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By
Application
16.2.1. Circulating
Tumor Cells (CTC) in the Blood
16.2.2. Cell
Free DNA from Tumor or Fetus Cells (in the blood)
16.2.3. Molecular
Diagnostics
16.2.4. Early
Stage Cancer
16.2.4.1. Lung
Cancer
16.2.4.2. Breast
Cancer
16.2.4.3. Colorectal
Cancer
16.2.4.4. Gastric
Cancer
16.2.4.5. Prostate
Cancer
16.2.4.6. Liver
Cancer
16.2.4.7. Bladder
Cancer
16.2.4.8. Ovarian
Cancer
16.2.4.9. Others
16.2.5. Non-invasive
Prenatal Tests (NIPT)
16.2.6. Others
16.3. Latin
America Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size
16.3.1. 5 ml
16.3.2. 50 ml
16.3.3. 100 ml
16.3.4. 250 ml
16.3.5. Above
250 ml
16.4. Latin
America Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By
Offering
16.4.1. Instruments
16.4.1.1. Blood
Collection Tube (BCT) for cfDNA and CTCs
16.4.1.2. Target
Selector Kits
16.4.1.3. Cell
Free DNA Extraction Kit
16.4.1.4. Cell
Free Nucleic Acid Extraction Kit
16.4.1.5. Mutation
Quantification Control Plasma
16.4.1.6. Genomic
Profiling Diagnostics kit
16.4.1.7. Target
Selector NGS Panels
16.4.1.8. PCR
Purification Kit
16.4.1.9. Blood
Nucleic Acid Extraction
16.4.1.10. Viral
Nucleic Acid Extraction
16.4.1.11. Others
16.4.2. Reagents
16.4.3. Liquid
Biopsy Assays
16.4.4. Tools
16.4.5. Services
16.4.5.1. Custom
Services
16.4.5.2. Support
Services
16.4.6. Others
16.5. Latin
America Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End
User
16.5.1. Hospitals/Clinics
16.5.2. Pathology
Laboratories
16.5.3. Physician
Laboratories
16.5.4. Academic
and Research Centers
16.5.5. Others
16.6. Latin
America Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By
Country
16.6.1. Brazil
16.6.1.1. Brazil
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application
16.6.1.1.1. Circulating
Tumor Cells (CTC) in the Blood
16.6.1.1.2. Cell
Free DNA from Tumor or Fetus Cells (in the blood)
16.6.1.1.3. Molecular
Diagnostics
16.6.1.1.4. Early
Stage Cancer
16.6.1.1.4.1. Lung
Cancer
16.6.1.1.4.2. Breast
Cancer
16.6.1.1.4.3. Colorectal
Cancer
16.6.1.1.4.4. Gastric
Cancer
16.6.1.1.4.5. Prostate
Cancer
16.6.1.1.4.6. Liver
Cancer
16.6.1.1.4.7. Bladder
Cancer
16.6.1.1.4.8. Ovarian
Cancer
16.6.1.1.4.9. Others
16.6.1.1.5. Non-invasive
Prenatal Tests (NIPT)
16.6.1.1.6. Others
16.6.1.2. Brazil
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size
16.6.1.2.1. 5
ml
16.6.1.2.2. 50
ml
16.6.1.2.3. 100
ml
16.6.1.2.4. 250
ml
16.6.1.2.5. Above
250 ml
16.6.1.3. Brazil
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering
16.6.1.3.1. Instruments
16.6.1.3.1.1. Blood
Collection Tube (BCT) for cfDNA and CTCs
16.6.1.3.1.2. Target
Selector Kits
16.6.1.3.1.3. Cell
Free DNA Extraction Kit
16.6.1.3.1.4. Cell
Free Nucleic Acid Extraction Kit
16.6.1.3.1.5. Mutation
Quantification Control Plasma
16.6.1.3.1.6. Genomic
Profiling Diagnostics kit
16.6.1.3.1.7. Target
Selector NGS Panels
16.6.1.3.1.8. PCR
Purification Kit
16.6.1.3.1.9. Blood
Nucleic Acid Extraction
16.6.1.3.1.10. Viral
Nucleic Acid Extraction
16.6.1.3.1.11. Others
16.6.1.3.2. Reagents
16.6.1.3.3. Liquid
Biopsy Assays
16.6.1.3.4. Tools
16.6.1.3.5. Services
16.6.1.3.5.1. Custom
Services
16.6.1.3.5.2. Support
Services
16.6.1.3.6. Others
16.6.1.4. Brazil
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User
16.6.1.4.1. Hospitals/Clinics
16.6.1.4.2. Pathology
Laboratories
16.6.1.4.3. Physician
Laboratories
16.6.1.4.4. Academic
and Research Centers
16.6.1.4.5. Others
16.6.2. Argentina
16.6.2.1. Argentina
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application
16.6.2.1.1. Circulating
Tumor Cells (CTC) in the Blood
16.6.2.1.2. Cell
Free DNA from Tumor or Fetus Cells (in the blood)
16.6.2.1.3. Molecular
Diagnostics
16.6.2.1.4. Early
Stage Cancer
16.6.2.1.4.1. Lung
Cancer
16.6.2.1.4.2. Breast
Cancer
16.6.2.1.4.3. Colorectal
Cancer
16.6.2.1.4.4. Gastric
Cancer
16.6.2.1.4.5. Prostate
Cancer
16.6.2.1.4.6. Liver
Cancer
16.6.2.1.4.7. Bladder
Cancer
16.6.2.1.4.8. Ovarian
Cancer
16.6.2.1.4.9. Others
16.6.2.1.5. Non-invasive
Prenatal Tests (NIPT)
16.6.2.1.6. Others
16.6.2.2. Argentina
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size
16.6.2.2.1. 5
ml
16.6.2.2.2. 50
ml
16.6.2.2.3. 100
ml
16.6.2.2.4. 250
ml
16.6.2.2.5. Above
250 ml
16.6.2.3. Argentina
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering
16.6.2.3.1. Instruments
16.6.2.3.1.1. Blood
Collection Tube (BCT) for cfDNA and CTCs
16.6.2.3.1.2. Target
Selector Kits
16.6.2.3.1.3. Cell
Free DNA Extraction Kit
16.6.2.3.1.4. Cell
Free Nucleic Acid Extraction Kit
16.6.2.3.1.5. Mutation
Quantification Control Plasma
16.6.2.3.1.6. Genomic
Profiling Diagnostics kit
16.6.2.3.1.7. Target
Selector NGS Panels
16.6.2.3.1.8. PCR
Purification Kit
16.6.2.3.1.9. Blood
Nucleic Acid Extraction
16.6.2.3.1.10. Viral
Nucleic Acid Extraction
16.6.2.3.1.11. Others
16.6.2.3.2. Reagents
16.6.2.3.3. Liquid
Biopsy Assays
16.6.2.3.4. Tools
16.6.2.3.5. Services
16.6.2.3.5.1. Custom
Services
16.6.2.3.5.2. Support
Services
16.6.2.3.6. Others
16.6.2.4. Argentina
Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User
16.6.2.4.1. Hospitals/Clinics
16.6.2.4.2. Pathology
Laboratories
16.6.2.4.3. Physician
Laboratories
16.6.2.4.4. Academic
and Research Centers
16.6.2.4.5. Others
16.6.3. Rest of
Latin America
16.6.3.1. Rest
of Latin America Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts,
By Application
16.6.3.1.1. Circulating
Tumor Cells (CTC) in the Blood
16.6.3.1.2. Cell
Free DNA from Tumor or Fetus Cells (in the blood)
16.6.3.1.3. Molecular
Diagnostics
16.6.3.1.4. Early
Stage Cancer
16.6.3.1.4.1. Lung
Cancer
16.6.3.1.4.2. Breast
Cancer
16.6.3.1.4.3. Colorectal
Cancer
16.6.3.1.4.4. Gastric
Cancer
16.6.3.1.4.5. Prostate
Cancer
16.6.3.1.4.6. Liver
Cancer
16.6.3.1.4.7. Bladder
Cancer
16.6.3.1.4.8. Ovarian
Cancer
16.6.3.1.4.9. Others
16.6.3.1.5. Non-invasive
Prenatal Tests (NIPT)
16.6.3.1.6. Others
16.6.3.2. Rest
of Latin America Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts,
By Size
16.6.3.2.1. 5
ml
16.6.3.2.2. 50
ml
16.6.3.2.3. 100
ml
16.6.3.2.4. 250
ml
16.6.3.2.5. Above
250 ml
16.6.3.3. Rest
of Latin America Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts,
By Offering
16.6.3.3.1. Instruments
16.6.3.3.1.1. Blood
Collection Tube (BCT) for cfDNA and CTCs
16.6.3.3.1.2. Target
Selector Kits
16.6.3.3.1.3. Cell
Free DNA Extraction Kit
16.6.3.3.1.4. Cell
Free Nucleic Acid Extraction Kit
16.6.3.3.1.5. Mutation
Quantification Control Plasma
16.6.3.3.1.6. Genomic
Profiling Diagnostics kit
16.6.3.3.1.7. Target
Selector NGS Panels
16.6.3.3.1.8. PCR
Purification Kit
16.6.3.3.1.9. Blood
Nucleic Acid Extraction
16.6.3.3.1.10. Viral
Nucleic Acid Extraction
16.6.3.3.1.11. Others
16.6.3.3.2. Reagents
16.6.3.3.3. Liquid
Biopsy Assays
16.6.3.3.4. Tools
16.6.3.3.5. Services
16.6.3.3.5.1. Custom
Services
16.6.3.3.5.2. Support
Services
16.6.3.3.6. Others
16.6.3.4. Rest
of Latin America Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts,
By End User
16.6.3.4.1. Hospitals/Clinics
16.6.3.4.2. Pathology
Laboratories
16.6.3.4.3. Physician
Laboratories
16.6.3.4.4. Academic
and Research Centers
16.6.3.4.5. Others
16.7. Key
Segment for Channeling Investments
16.7.1. By
Country
16.7.2. By
Application
16.7.3. By Size
16.7.4. By
Offering
16.7.5. By End
User
17. Competitive
Benchmarking
17.1. Market
Share Analysis, 2021
17.2. Global
Presence and Growth Strategies
17.2.1. Mergers
and Acquisitions
17.2.2. Product
Launches
17.2.3. Investments
Trends
17.2.4. R&D
Initiatives
18. Player
Profiles
18.1. Biocept,
Inc.
18.1.1. Company
Details
18.1.2. Company
Overview
18.1.3. Product
Offerings
18.1.4. Key
Developments
18.1.5. Financial
Analysis
18.1.6. SWOT
Analysis
18.1.7. Business
Strategies
18.2. BioChain
Institute Inc.
18.2.1. Company
Details
18.2.2. Company
Overview
18.2.3. Product
Offerings
18.2.4. Key
Developments
18.2.5. Financial
Analysis
18.2.6. SWOT
Analysis
18.2.7. Business
Strategies
18.3. Bio-Rad
Laboratories, Inc.
18.3.1. Company
Details
18.3.2. Company
Overview
18.3.3. Product
Offerings
18.3.4. Key
Developments
18.3.5. Financial
Analysis
18.3.6. SWOT
Analysis
18.3.7. Business
Strategies
18.4. F. Hoffmann-La
Roche Ltd
18.4.1. Company
Details
18.4.2. Company
Overview
18.4.3. Product
Offerings
18.4.4. Key
Developments
18.4.5. Financial
Analysis
18.4.6. SWOT
Analysis
18.4.7. Business
Strategies
18.5. Genomic
Health
18.5.1. Company
Details
18.5.2. Company
Overview
18.5.3. Product
Offerings
18.5.4. Key
Developments
18.5.5. Financial
Analysis
18.5.6. SWOT
Analysis
18.5.7. Business
Strategies
18.6. Grail Bio
in collaboration an Illumina spinoff
18.6.1. Company
Details
18.6.2. Company
Overview
18.6.3. Product
Offerings
18.6.4. Key
Developments
18.6.5. Financial
Analysis
18.6.6. SWOT
Analysis
18.6.7. Business
Strategies
18.7. Guardant
Health
18.7.1. Company
Details
18.7.2. Company
Overview
18.7.3. Product
Offerings
18.7.4. Key
Developments
18.7.5. Financial
Analysis
18.7.6. SWOT
Analysis
18.7.7. Business
Strategies
18.8. MDxHealth.
18.8.1. Company
Details
18.8.2. Company
Overview
18.8.3. Product
Offerings
18.8.4. Key
Developments
18.8.5. Financial
Analysis
18.8.6. SWOT
Analysis
18.8.7. Business
Strategies
18.9. Myriad
Genetics
18.9.1. Company
Details
18.9.2. Company
Overview
18.9.3. Product
Offerings
18.9.4. Key
Developments
18.9.5. Financial
Analysis
18.9.6. SWOT
Analysis
18.9.7. Business
Strategies
18.10. Pathway
Genomics
18.10.1. Company
Details
18.10.2. Company
Overview
18.10.3. Product
Offerings
18.10.4. Key
Developments
18.10.5. Financial
Analysis
18.10.6. SWOT
Analysis
18.10.7. Business
Strategies
18.11. Personal
Genome Diagnostics Inc.
18.11.1. Company
Details
18.11.2. Company
Overview
18.11.3. Product
Offerings
18.11.4. Key
Developments
18.11.5. Financial
Analysis
18.11.6. SWOT
Analysis
18.11.7. Business
Strategies
18.12. QIAGEN
18.12.1. Company
Details
18.12.2. Company
Overview
18.12.3. Product
Offerings
18.12.4. Key
Developments
18.12.5. Financial
Analysis
18.12.6. SWOT
Analysis
18.12.7. Business
Strategies
18.13. Other
Market Participants
19. Key
Findings
Note: This ToC is
tentative and can be changed according to the research study conducted during
the course of report completion.
**Exclusive for
Multi-User and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.